<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAN</journal-id>
<journal-id journal-id-type="hwp">sptan</journal-id>
<journal-title>Therapeutic Advances in Neurological Disorders</journal-title>
<issn pub-type="ppub">1756-2856</issn>
<issn pub-type="epub">1756-2864</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1756285611423412</article-id>
<article-id pub-id-type="publisher-id">10.1177_1756285611423412</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Borgohain</surname><given-names>Rupam</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Kandadai</surname><given-names>Rukmini Mridula</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Jabeen</surname><given-names>Afshan</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Kannikannan</surname><given-names>Meena A.</given-names></name>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1756285611423412">Rupam Borgohain, Professor of Neurology, Department of Neurology, Nizam’s Institute of Medical Sciences, Punjagutta, Hyderabad 500082, India <email>rupamb@hotmail.com</email></corresp>
<corresp id="corresp2-1756285611423412">Rukmini Mridula Kandadai Afshan Jabeen Meena A. Kannikannan Department of Neurology, Nizam’s Institute of Medical Sciences, Hyderabad, India</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>5</volume>
<issue>1</issue>
<fpage>23</fpage>
<lpage>41</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Nonmotor symptoms are an integral part of Parkinson’s disease and cause significant morbidity. Pharmacological therapy helps alleviate the disease but produces nonmotor manifestations. While deep brain stimulation (DBS) has emerged as the treatment of choice for motor dysfunction, the effect on nonmotor symptoms is not well known. Compared with pharmacological therapy, bilateral subthalamic nucleus (STN)-DBS or globus pallidum interna (GPi)-DBS has significant beneficial effects on pain, sleep, gastrointestinal and urological symptoms. STN-DBS is associated with a mild worsening in verbal fluency while GPi-DBS has no effect on cognition. STN-DBS may improve cardiovascular autonomic disturbances by reducing the dose of dopaminergic drugs. Because the motor effects of STN-DBS and GPi-DBS appear to be similar, nonmotor symptoms may determine the target choice in surgery of future patients.</p>
</abstract>
<kwd-group>
<kwd>Parkinson’s disease</kwd>
<kwd>deep brain stimulation</kwd>
<kwd>dopaminergic drugs</kwd>
<kwd>globus pallidum interna deep brain stimulation</kwd>
<kwd>nonmotor symptoms</kwd>
<kwd>pharmacological therapy</kwd>
<kwd>subthalamic nucleus deep brain stimulation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1756285611423412" sec-type="intro">
<title>Introduction</title>
<p>The pathology of Parkinson’s disease (PD) extends far beyond the nigrostriatal system and results in nonmotor symptoms coexisting with motor symptoms. Nonmotor symptoms can precede motor symptoms by years and are common in all stages of PD.They cause significant morbidity [<xref ref-type="bibr" rid="bibr71-1756285611423412">Lim and Lang, 2010</xref>] and are often under recognized by health professionals [<xref ref-type="bibr" rid="bibr95-1756285611423412">Parsons <italic>et al</italic>. 2006</xref>]. They can be divided into four domains: neuropsychiatric, autonomic, sleep and sensory dysfunction [<xref ref-type="bibr" rid="bibr71-1756285611423412">Lim and Lang, 2010</xref>].</p>
<p>The effects of dopamine replacement therapy (DRT) and deep brain stimulation (DBS) on motor symptoms are well known. DBS has been shown to be more effective than the best medical therapy in improving ‘on’ time without troubling dyskinesias by 4.6 h/day, motor function in 71% <italic>versus</italic> 36% on medical therapy, and in quality of life 6 months after surgery [<xref ref-type="bibr" rid="bibr140-1756285611423412">Weaver <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr91-1756285611423412">Pahwa <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr52-1756285611423412">Goetz <italic>et al</italic>. 2005</xref>]. This improvement was seen equally in bilateral DBS of the subthalamic nucleus (STN) and globus pallidum interna (GPi) [<xref ref-type="bibr" rid="bibr45-1756285611423412">Follet <italic>et al</italic>. 2010</xref>].</p>
<p>The effect of various therapeutic modalities on nonmotor symptoms is still unclear. This review compares the effects of DBS and various dopaminergic drugs on nonmotor symptoms of PD.</p>
</sec>
<sec id="section2-1756285611423412" sec-type="methods">
<title>Methodology</title>
<p>A literature search using PubMed databases was carried out for the effect of DBS and various antiparkinsonian medications on nonmotor symptoms using the following search words/phrases: deep brain stimulation, dopamine replacement, dopaminergic agonists, monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase inhibitors, and cognition, behavioural abnormalities, autonomic involvement, autonomic disturbances, cardiovascular autonomic differences, gastrointestinal changes, micturition, sexual abnormalities, sleep disorders, pain, olfaction. The search yielded 2789 articles. Controlled studies that performed a head-to-head comparison of patients on DRT and after DBS are few and are listed in <xref ref-type="table" rid="table1-1756285611423412">Table 1</xref>. These included 22 publications, 17 on neuropsychiatric symptoms, two on cardiovascular autonomic functions, one on sleep and two on quality of life. Subsequently, from PubMed indexed articles, additional reports were included after reference analysis if they evaluated the effect of DRT alone (<xref ref-type="table" rid="table2-1756285611423412">Table 2</xref>) or DBS on various nonmotor symptoms, especially when there are no clear head-to-head comparison studies. Studies comparing the effect of DRT or DBS on overall nonmotor symptoms are given in <xref ref-type="table" rid="table3-1756285611423412">Table 3</xref>.</p>
<table-wrap id="table1-1756285611423412" position="float">
<label>Table 1.</label>
<caption><p>Controlled studies comparing patients receiving dopamine replacement therapy (DRT) <italic>versus</italic> deep brain stimulation (DBS).</p></caption>
<graphic alternate-form-of="table1-1756285611423412" xlink:href="10.1177_1756285611423412-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Series</th>
<th align="left">Type of study</th>
<th align="left">PatientsreceivingDBS (<italic>n</italic>)</th>
<th align="left">PatientsreceivingDRT (<italic>n</italic>)</th>
<th align="left">Nonmotor symptomstudied</th>
<th align="left">Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>[<xref ref-type="bibr" rid="bibr51-1756285611423412">Gironell <italic>et al</italic>. 2003</xref>]</td>
<td>Controlled</td>
<td>8</td>
<td>8</td>
<td>Cognition</td>
<td>Worsening of semantic verbal fluency at 6 months after STN-DBS</td>
</tr>
<tr>
<td>2</td>
<td>[<xref ref-type="bibr" rid="bibr82-1756285611423412">Morrison <italic>et al</italic>. 2004</xref>]</td>
<td>Controlled</td>
<td>17</td>
<td>11</td>
<td>Cognition andbehaviour</td>
<td>Mild decline in delayed verbal recall and language functions 13.3 (7.8) weeks after STN-DBS. No effect on depression</td>
</tr>
<tr>
<td>3</td>
<td>[<xref ref-type="bibr" rid="bibr116-1756285611423412">Smeding <italic>et al</italic>. 2006</xref>]</td>
<td>Controlled</td>
<td>99</td>
<td>36</td>
<td>Cognition andbehaviour</td>
<td>Decline in verbal fluency, colour naming, selective attention, and verbal memory after DBS. Decrease in positive affect, depression, increased emotional lability 6 months after DBS. Psychiatric complications: 9% STN-DBS <italic>versus</italic> 3% DRT</td>
</tr>
<tr>
<td>4</td>
<td>[<xref ref-type="bibr" rid="bibr27-1756285611423412">Castner <italic>et al</italic>. 2008</xref>]</td>
<td>Controlled</td>
<td>8</td>
<td>15</td>
<td>Cognition</td>
<td>Reduced noun-verb generation after STN-DBS</td>
</tr>
<tr>
<td>5</td>
<td>[<xref ref-type="bibr" rid="bibr151-1756285611423412">York <italic>et al</italic>. 2008</xref>]</td>
<td>Controlled</td>
<td>23</td>
<td>28</td>
<td>Cognition andbehaviour</td>
<td>Declines in verbal recall and trends for declines in oral information processing 6 months after DBS surgery. No change in depression, anxiety or psychological distress scores</td>
</tr>
<tr>
<td>6</td>
<td>[<xref ref-type="bibr" rid="bibr34-1756285611423412">Daniels <italic>et al</italic>. 2010</xref>;<xref ref-type="bibr" rid="bibr150-1756285611423412">Witt <italic>et al</italic>. 2008</xref>]</td>
<td>Randomizedcontrolled</td>
<td>60</td>
<td>63</td>
<td>Cognition andbehaviour</td>
<td>Impairment in phonemic and semantic fluency, set shifting (executive domain) improvement in anxiety scores in DBS group 6 months after surgery</td>
</tr>
<tr>
<td>7</td>
<td>[<xref ref-type="bibr" rid="bibr140-1756285611423412">Weaver <italic>et al</italic>. 2009</xref>]</td>
<td>Randomizedcontrolled</td>
<td>121</td>
<td>134</td>
<td>Cognition</td>
<td>Mild impairment in working memory, processing speed, phonemic fluency and delayed recall in DBS group. No change in depression scales</td>
</tr>
<tr>
<td>8</td>
<td>[<xref ref-type="bibr" rid="bibr153-1756285611423412">Zangaglia <italic>et al</italic>. 2009</xref>]</td>
<td>Controlled</td>
<td>32</td>
<td>33</td>
<td>Cognition</td>
<td>Logical executive function tasks and verbal fluency reduced in first 6 months, improved at 12 months and stable at 36 months. Verbal fluency was worse in DBS <italic>versus</italic> DRT at 36 months</td>
</tr>
<tr>
<td>9</td>
<td>[<xref ref-type="bibr" rid="bibr25-1756285611423412">Castelli <italic>et al</italic>. 2010</xref>]</td>
<td>Controlled</td>
<td>27</td>
<td>31</td>
<td>Cognition</td>
<td>Phonemic verbal fluency declined 1 year after DBS-STN</td>
</tr>
<tr>
<td>10</td>
<td>[<xref ref-type="bibr" rid="bibr144-1756285611423412">Williams <italic>et al</italic>. 2011</xref>]</td>
<td>Controlled</td>
<td>19</td>
<td>18</td>
<td>Cognition</td>
<td>Impairments in nonverbal recall, oral information processing speed, and lexical and semantic fluency in STN-DBS compared with DRT 2 years after surgery</td>
</tr>
<tr>
<td>11</td>
<td>[<xref ref-type="bibr" rid="bibr7-1756285611423412">Antonini <italic>et al</italic>. 2011</xref>;<xref ref-type="bibr" rid="bibr35-1756285611423412">De Gasperi <italic>et al</italic>. 2006</xref>]</td>
<td>Controlled</td>
<td>13</td>
<td>12 onsub cutaneousapomorphineinfusion</td>
<td>Behaviour</td>
<td>Worsening on NPI scores for depression after 12 months of STN-DBS. Category fluency also declined. 12 patients reached 5-year follow up in STN-DBS group compared with 2 on subcutaneous apomorphine. Worsening on NPI scores for depression in STN group at 5 years</td>
</tr>
<tr>
<td>12</td>
<td>[<xref ref-type="bibr" rid="bibr26-1756285611423412">Castelli <italic>et al</italic>. 2008</xref>]</td>
<td>Controlled</td>
<td>25</td>
<td>25</td>
<td>Behaviour</td>
<td>No significant differences in mood (BDI) or state and trait anxiety scores (STAI X1-X2). Obsessive–compulsive traits significantly lower in DBS group at 3 years</td>
</tr>
<tr>
<td>13</td>
<td>[<xref ref-type="bibr" rid="bibr139-1756285611423412">Wang <italic>et al</italic>. 2009</xref>]</td>
<td>Controlled</td>
<td>27</td>
<td>27</td>
<td>Behaviour</td>
<td>Depression scores improved at 3 and 6 months correlating with improved motor scores but long-term benefits unremarkable</td>
</tr>
<tr>
<td>14</td>
<td>[<xref ref-type="bibr" rid="bibr66-1756285611423412">Kirsh-Darrow <italic>et al</italic>. 2011</xref>]</td>
<td>Controlled</td>
<td>48</td>
<td>48</td>
<td>Apathy</td>
<td>Apathy increased linearly in STN-DBS group by 0.66 points/month for 6 months</td>
</tr>
<tr>
<td>15</td>
<td>[<xref ref-type="bibr" rid="bibr123-1756285611423412">Strutt <italic>et al</italic>. 2011</xref>]</td>
<td>Controlled</td>
<td>17</td>
<td>22</td>
<td>Behaviour</td>
<td>Increase in cognitive-emotional symptoms of depression and psychological symptoms of distress and anxiety in STN-DBS group at 6 months</td>
</tr>
<tr>
<td>16</td>
<td>[<xref ref-type="bibr" rid="bibr74-1756285611423412">Lulé <italic>et al</italic>. 2011</xref>]</td>
<td>Controlled</td>
<td>15</td>
<td>15</td>
<td>Behaviour</td>
<td>DRT group worse in the gambling task <italic>versus</italic> STN-DBS in ‘off’ state. DBS ‘on’, differences in performance were less pronounced</td>
</tr>
<tr>
<td>17</td>
<td>[<xref ref-type="bibr" rid="bibr90-1756285611423412">Oyama <italic>et al</italic>. 2011</xref>]</td>
<td>Controlled</td>
<td>16</td>
<td>16</td>
<td>Behaviour</td>
<td>Performance in Iowa gambling test worse in DBS ‘on’ state compared with DBS ‘off’ session (<italic>p</italic> = 0.019) only in the last block</td>
</tr>
<tr>
<td>18</td>
<td>[<xref ref-type="bibr" rid="bibr73-1756285611423412">Ludwig <italic>et al</italic>. 2007</xref>]</td>
<td>Controlled</td>
<td>14</td>
<td>15</td>
<td>Cardiovascularautonomic function</td>
<td>Levodopa worsens orthostatic hypotension. No effect of STN-DBS</td>
</tr>
<tr>
<td>19</td>
<td>[<xref ref-type="bibr" rid="bibr60-1756285611423412">Holmberg <italic>et al</italic>. 2005</xref>]</td>
<td>Controlled</td>
<td>11</td>
<td>8</td>
<td>Cardiovascularautonomic functions</td>
<td>Heart rate variability and blood pressure response to orthostatic provocation was reduced in both groups</td>
</tr>
<tr>
<td>20</td>
<td>[<xref ref-type="bibr" rid="bibr59-1756285611423412">Hjort <italic>et al</italic>. 2004</xref>]</td>
<td>Controlled</td>
<td>10</td>
<td>10</td>
<td>Sleep</td>
<td>Significant improvement of nocturnal motor symptoms and overall sleep quality after DBS after 3 months. Nocturia, sleep fragmentation, and daytime sleepiness were unaffected</td>
</tr>
<tr>
<td>21</td>
<td>[<xref ref-type="bibr" rid="bibr37-1756285611423412">Deuschl <italic>et al</italic>. 2006</xref>]</td>
<td>Randomized controlled</td>
<td>78</td>
<td>78</td>
<td>HRQoL</td>
<td>PDQ-39, significant improvement in overall score and domain of mobility, activities of daily living, emotional well being and stigma in STN-DBS group</td>
</tr>
<tr>
<td>22</td>
<td>[<xref ref-type="bibr" rid="bibr143-1756285611423412">Williams <italic>et al</italic>. 2010</xref>]</td>
<td>Randomized controlled</td>
<td>183</td>
<td>183</td>
<td>HRQoL</td>
<td>PDQ-39, significant improvement in overall score and domain of mobility, activities of daily living and stigma in STN-DBS group</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1756285611423412">
<p>BDI, Beck Depression Inventory; HRQoL, health-related quality of life; NPI, Neuropsychiatric Inventory; PDQ-39, 39-item Parkinson’s Disease Questionnaire; STAI, State–Trait Anxiety Inventory; STN, subthalamic nucleus.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-1756285611423412" position="float">
<label>Table 2.</label>
<caption><p>Effect of dopaminergic therapy on nonmotor symptoms of Parkinson’s disease (PD).</p></caption>
<graphic alternate-form-of="table2-1756285611423412" xlink:href="10.1177_1756285611423412-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Series</th>
<th align="left">Type of study</th>
<th align="left">Medication studies</th>
<th align="left">Nonmotor symptomstudied</th>
<th align="left">Duration</th>
<th align="left">Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>[<xref ref-type="bibr" rid="bibr61-1756285611423412">Jahanshahi <italic>et al</italic>. 2010</xref>]</td>
<td>Controlled with 11 patients with PD and 13 controls</td>
<td>Levodopa</td>
<td>Cognition</td>
<td>Single dose</td>
<td>Performed worse on learning in weather prediction task</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr103-1756285611423412">Rektorová <italic>et al</italic>. 2005</xref>]</td>
<td>Series of 41 patients with PD with one episode of depression</td>
<td>Pramipexole, pergolide</td>
<td>Cognition, depression and motor symptoms</td>
<td>8 months</td>
<td>Depression improved in pramipexole arm, motor symptoms improved in all patients and cognition was same in both groups</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr32-1756285611423412">Costa <italic>et al</italic>. 2009</xref>]</td>
<td>Controlled study with 19 patients with PD and 13 healthy controls</td>
<td>Pramipexole, pergolide</td>
<td>Cognition</td>
<td>Single dose</td>
<td>Working memory improved with both pramipexole and pergolide</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr21-1756285611423412">Brusa <italic>et al</italic>. 2003</xref>]</td>
<td>Series of 20 patients in ‘off’ state, ‘on’ with levodopa, pramipexole</td>
<td>Pramipexole</td>
<td>Cognition</td>
<td>Single dose</td>
<td>Significant impairment of short-term verbal memory, attentional-executive functions and verbal fluency, with pramipexole. Levodopa improved executive function</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr11-1756285611423412">Barone <italic>et al</italic>. 2010</xref>]</td>
<td>Double-blind randomised control trial with 287 patients (139 <italic>versus</italic> 148)</td>
<td>Pramipexole</td>
<td>BDI score</td>
<td>12 weeks</td>
<td>BDI scores decreased by mean 5.9 points in pramipexole group compared with 4.0 points</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr70-1756285611423412">Leentjens <italic>et al</italic>. 2009</xref>]</td>
<td>Meta-analysis, 480 patients with PD were analysed for mood and 570 for motivation</td>
<td>Pramipexole</td>
<td>Mood and motivation</td>
<td>Varying in different studies</td>
<td>Improvement in both mood and motivation after pramipexole therapy</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr101-1756285611423412">Rascol <italic>et al</italic>. 2000</xref>]</td>
<td>Double-blind randomized control trial of 268 patients, 179 ropinirole <italic>versus</italic> 89 levodopa</td>
<td>Levodopa <italic>versus</italic> ropinirole</td>
<td>Neuropsychiatric</td>
<td>5 years</td>
<td>Hallucinations more in ropinirole (31%) compared with levodopa group</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr104-1756285611423412">Rektorová <italic>et al</italic>. 2008</xref>]</td>
<td>Study of 44 patients with PD with or without motor complications</td>
<td>Ropinirole</td>
<td>Anxiety, depression, sleep and sexual function</td>
<td>6 months</td>
<td>Ropinirole improved both anxiety and depressive symptoms in patients with motor fluctuations. No change in sleep or sexual functions</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr92-1756285611423412">Pahwa <italic>et al</italic>. 2007</xref>]</td>
<td>Double-blind placebo-controlled trial of 393 patients with PD</td>
<td>24 h extended release ropinirole</td>
<td>Mood, behaviour and sleep</td>
<td>24 weeks</td>
<td>Improvement in scores of depression, PDQ-39 and PD sleep scale</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr141-1756285611423412">Weintraub <italic>et al</italic>. 2006</xref>]</td>
<td>Cohort of 272 patients with idiopathic PD</td>
<td>Dopaminergic therapy</td>
<td>ICD</td>
<td>Single point interview</td>
<td>Treatment with a dopamine agonist (<italic>p</italic> = 0.01) and a history of ICD symptoms prior to PD onset (<italic>p</italic> = 0.02) predicted current ICD</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr127-1756285611423412">Tateno <italic>et al</italic>. 2011</xref>]</td>
<td>Series with 19 patients</td>
<td>Levodopa</td>
<td>Constipation, QL-GAT</td>
<td>3 months</td>
<td>Levodopa augmented rectal contraction, lessened paradoxical sphincter contraction, and reduced constipation</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr132-1756285611423412">Trenkwalder <italic>et al</italic>. 2011</xref>]</td>
<td>Double-blind randomized control trial with 287 patients (197 rotigotine and 97 placebo)</td>
<td>Rotigotine</td>
<td>Sleep</td>
<td>12 weeks</td>
<td>Significant improvement in nocturnal sleep scores</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr31-1756285611423412">Comella <italic>et al</italic>. 2005</xref>]</td>
<td>Double-blind placebo-controlled study of 22 patients with PD</td>
<td>Pergolide</td>
<td>Sleep</td>
<td>Single dose</td>
<td>The pergolide group worsened in actigraphic measures of sleep efficiency and sleep fragmentation</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr100-1756285611423412">Pursiainen <italic>et al</italic>. 2007</xref>]</td>
<td>Controlled study of 16 patients with PD with wearing off, 15 without motor fluctuations, 16 healthy controls</td>
<td>Dopaminergic therapy</td>
<td>Sweating and UPDRS score before and after medication</td>
<td>4 h</td>
<td>The patients with motor fluctuations had significantly higher sweating rate during highest UPDRS motor score phase compared with healthy controls</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr49-1756285611423412">Gerdelat-Mas <italic>et al</italic>. 2007</xref>]</td>
<td>Controlled study of 13 patients with PD and 10 controls</td>
<td>Levodopa</td>
<td>RIII (pain threshold)</td>
<td>Single dose</td>
<td>RIII threshold was lower in patients with PD. Levodopa increased the threshold</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr18-1756285611423412">Brefel-Courbon <italic>et al</italic>. 2005</xref>]</td>
<td>Controlled study of 9 patients with PD and 9 controls</td>
<td>Levodopa</td>
<td>Pain threshold, H2 15O PET analysis of regional cerebral blood flow</td>
<td>Single dose</td>
<td>Pain threshold lower with higher pain-induced activation in nociceptive pathways in patients with PD which returns to normal after levodopa</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr36-1756285611423412">Dellapina <italic>et al</italic>. 2011</xref>]</td>
<td>Controlled study of 25 patients with PD</td>
<td>Subcutaneous apomorphine</td>
<td>Subjective pain threshold, objective-nociceptive flexion test and PET</td>
<td>Single dose</td>
<td>No effect in pain processing</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr114-1756285611423412">Slaoui <italic>et al</italic>. 2007</xref>]</td>
<td>Series of 20 patients with PD</td>
<td>Levodopa</td>
<td>Heat and cold pain thresholds</td>
<td>Pain</td>
<td>Levodopa increased heat and cold pain thresholds and heat pain tolerance in patient with PD</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1756285611423412">
<p>BDI, Beck Depression Inventory; ICD, impulse control disorder; PDQ-39, 39-item Parkinson’s Disease Questionnaire; PET, positron emission tomography; RIII, nociceptive flexion response; QL-GAT, quantitative lower-gastrointestinal autonomic test; UPDRS, Unified Parkinson’s Disease Rating Scale.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-1756285611423412" position="float">
<label>Table 3.</label>
<caption><p>Studies comparing overall nonmotor symptoms in dopamine replacement therapy (DRT) and deep brain stimulation (DBS) groups individually.</p></caption>
<graphic alternate-form-of="table3-1756285611423412" xlink:href="10.1177_1756285611423412-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Series</th>
<th align="left">DBS <italic>versus</italic> DRT</th>
<th align="left">Scale used</th>
<th align="left">Patients (<italic>n</italic>)</th>
<th align="left">Duration after DBS</th>
<th align="left">Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>[<xref ref-type="bibr" rid="bibr149-1756285611423412">Witjas <italic>et al</italic>. 2007</xref>]</td>
<td>STN-DBS</td>
<td>Structured questionnaire on nonmotor fluctuations</td>
<td>41</td>
<td>1 year</td>
<td>Pain and sensory fluctuations reduced by 84.2%, cognitive 70.5%, dysautonomic 63%</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr155-1756285611423412">Zibetti <italic>et al</italic>. 2007</xref>]</td>
<td>STN-DBS</td>
<td>Items from UPDRS. Question on constipation and urological dysfunction</td>
<td>36</td>
<td>12 and 24 months after DBS</td>
<td>Sleep and constipation improved</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr65-1756285611423412">Kim <italic>et al</italic>. 2009</xref>]</td>
<td>DRT</td>
<td>NMSS</td>
<td>23</td>
<td>3 months</td>
<td>No change in number of nonmotor symptoms or NMSS in 16 patients</td>
</tr>
<tr>
<td>[<xref ref-type="bibr" rid="bibr84-1756285611423412">Nazarro <italic>et al</italic>. 2011</xref>]</td>
<td>DBS</td>
<td>NMS Quest and PDQ-39</td>
<td>24</td>
<td>1 year</td>
<td>Mean number of symptoms reduced from 12 to 7. Maximum reduction in autonomic symptoms with improvement in quality of life and subscales of mobility, activities of daily living, cognition and bodily discomfort</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1756285611423412">
<p>NMS Quest, Nonmotor Symptoms Questionnaire; NMSS, Nonmotor Symptoms Assessment Scale; PDQ-39, 39-item Parkinson’s Disease Questionnaire; STN, subthalamic nucleus; UPDRS, Unified Parkinson’s Disease Rating Scale.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section3-1756285611423412">
<title>Review</title>
<p>The effects of DBS and DRT on each nonmotor domain are described below.</p>
<sec id="section4-1756285611423412">
<title>Neuropsychiatric dysfunction</title>
<p>Cognitive and behavioural changes are common nonmotor symptoms which can impair social and occupational functioning of patients. Cognitive abnormalities in PD are characterized by dysfunction in various domains of executive function, language, memory, vision and psychomotor speed [<xref ref-type="bibr" rid="bibr71-1756285611423412">Lim and Lang, 2010</xref>].</p>
<sec id="section5-1756285611423412">
<title>Cognition</title>
<p>Studies on the effects of DBS on cognition have shown differing results. This is partly because of the inhomogeneity in neuropsychological tests and patient population characteristics in these studies. This is also evident in various meta-analyses and reviews. While recent meta-analyses have shown mild worsening of cognition, with cognitive problems in 41% of patients after STN-DBS [<xref ref-type="bibr" rid="bibr128-1756285611423412">Temel <italic>et al</italic>. 2006</xref>] and a moderate decline in semantic and phonemic verbal fluency [<xref ref-type="bibr" rid="bibr95-1756285611423412">Parsons <italic>et al</italic>. 2006</xref>], another review by Halpern and colleagues showed mixed results. Improvement in working memory, psychomotor speed and visuomotor sequencing was noted in some studies while worsening in tests of executive function – verbal fluency, memory and language functions – were noted in other studies [<xref ref-type="bibr" rid="bibr55-1756285611423412">Halpern <italic>et al</italic>. 2009</xref>].</p>
<p>It is still unclear how the trajectory, stimulation parameters and position of DBS electrodes modify cognitive functions. A comparison of 299 patients with bilateral DBS, either STN or GPi, showed similar cognitive functions in both groups except for a decrease in visual processing speed in patients with STN-DBS [<xref ref-type="bibr" rid="bibr45-1756285611423412">Follet <italic>et al</italic>. 2010</xref>]. Two other randomized, controlled studies, which compared the cognitive outcome of bilateral STN-DBS <italic>versus</italic> GPi-DBS [<xref ref-type="bibr" rid="bibr109-1756285611423412">Rothlind <italic>et al</italic>. 2007</xref>] and unilateral STN-DBS <italic>versus</italic> GPi-DBS [<xref ref-type="bibr" rid="bibr87-1756285611423412">Okun <italic>et al</italic>. 2009</xref>], found no significant difference in the cognitive outcomes, although there was a greater decline in letter verbal fluency in the STN-DBS group [<xref ref-type="bibr" rid="bibr87-1756285611423412">Okun <italic>et al</italic>. 2009</xref>].</p>
<p>The exact location of the electrodes has an impact on cognitive outcome. In a study comparing unilateral STN <italic>versus</italic> GPi stimulation, there were no impairment in measures of mood and cognition when electrodes in the optimal locations of GPi or STN were stimulated, in contrast to adverse mood effects on stimulation of ventral locations in both targets [<xref ref-type="bibr" rid="bibr87-1756285611423412">Okun <italic>et al</italic>. 2009</xref>].</p>
<p>There are very few studies on unilateral DBS. Cognition may be better preserved in these patients. In a recent study bilateral STN-DBS worsened cognitive and motor function in modest dual task conditions more than unilateral DBS [<xref ref-type="bibr" rid="bibr2-1756285611423412">Alberts <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr56-1756285611423412">Hershey <italic>et al</italic>. 2004</xref>]. This motor and cognitive worsening with bilateral STN-DBS was minimized with stimulation parameters that reduced current spread to nonmotor areas of the brain [<xref ref-type="bibr" rid="bibr46-1756285611423412">Frankemolle <italic>et al</italic>. 2010</xref>].</p>
<p>Most dopaminergic agonists [<xref ref-type="bibr" rid="bibr103-1756285611423412">Rektorová <italic>et al</italic>. 2005</xref>] showed no effect on cognition. While a few studies on dopaminergic agonists and MAO-B inhibitors have shown improvement in executive function and memory [<xref ref-type="bibr" rid="bibr32-1756285611423412">Costa <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr125-1756285611423412">Takahata <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr118-1756285611423412">Speiser <italic>et al</italic>. 1998</xref>], others have demonstrated worsening of cognition by increased sedation, confusion or hallucinations [Jahanshahi <italic>et al</italic>.2010; <xref ref-type="bibr" rid="bibr21-1756285611423412">Brusa <italic>et al</italic>. 2003</xref>].</p>
<p>Comparative studies of cognition of patients undergoing DBS with a control group on DRT are few and listed in <xref ref-type="table" rid="table1-1756285611423412">Table 1</xref>. Most studies, including a large randomized, blinded assessment trial, have shown a mild but significant reduction in verbal fluency at the end of 6–12 months in patients who underwent STN-DBS compared with best medical treatment [<xref ref-type="bibr" rid="bibr144-1756285611423412">Williams <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr25-1756285611423412">Castelli <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr34-1756285611423412">Daniels <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr140-1756285611423412">Weaver <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr153-1756285611423412">Zangaglia <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr150-1756285611423412">Witt <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr151-1756285611423412">York <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr116-1756285611423412">Smeding <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr82-1756285611423412">Morrison <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr51-1756285611423412">Gironell <italic>et al</italic>. 2003</xref>]. A few studies have shown worsening in other tests of executive function [<xref ref-type="bibr" rid="bibr140-1756285611423412">Weaver <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr144-1756285611423412">Williams <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr153-1756285611423412">Zangaglia <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr150-1756285611423412">Witt <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr116-1756285611423412">Smeding <italic>et al</italic>. 2006</xref>] and verbal memory [<xref ref-type="bibr" rid="bibr144-1756285611423412">Williams <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr140-1756285611423412">Weaver <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr151-1756285611423412">York <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr116-1756285611423412">Smeding <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr82-1756285611423412">Morrison <italic>et al</italic>. 2004</xref>].</p>
<p>Controlled studies have looked at the short-term effects of DBS and DRT on cognition. Zangaglia and colleagues compared the effect of bilateral STN-DBS with standard medical therapy at 3-year follow up and found a reduction in verbal fluency scores in the surgical arm associated with a short-term transient worsening of frontal executive function [<xref ref-type="bibr" rid="bibr153-1756285611423412">Zangaglia <italic>et al</italic>. 2009</xref>]. A recent study of 20 patients examined the effect of bilateral STN-DBS 8 years after surgery and showed slight but persistent reduction in verbal fluency, abstract reasoning, executive function and episodic memory [<xref ref-type="bibr" rid="bibr42-1756285611423412">Fasano <italic>et al</italic>. 2010</xref>]. One patient developed dementia at 5 years and their condition continued to worsen at 8 years [<xref ref-type="bibr" rid="bibr42-1756285611423412">Fasano <italic>et al</italic>. 2010</xref>].</p>
<p>While impairment in cognition after STN-DBS is mild in most patients [<xref ref-type="bibr" rid="bibr55-1756285611423412">Halpern <italic>et al</italic>. 2009</xref>], patients with impaired attention, advanced age and a low levodopa response at baseline seem to be more vulnerable to cognitive decline after STN-DBS [<xref ref-type="bibr" rid="bibr115-1756285611423412">Smeding <italic>et al</italic>. 2011</xref>]. Thus cognition is slightly impaired after STN-DBS and a strict selection of appropriate patients for surgery may be useful to prevent worsening of cognition.</p>
</sec>
<sec id="section6-1756285611423412">
<title>Behaviour and mood</title>
<p>Various psychiatric disorders ranging from mood disorders – depression, mania, anxiety and apathy – to hallucinations and psychosis are seen in patients with PD on long-term medical management [<xref ref-type="bibr" rid="bibr154-1756285611423412">Zgaljardic <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr1-1756285611423412">Aarsland <italic>et al</italic>. 1999</xref>]. DRT, especially dopamine agonists, can cause or aggravate a variety of complex repetitive or reward-based behavioural disorders such as impulse control disorders, punding and dopamine dysregulation syndrome [<xref ref-type="bibr" rid="bibr40-1756285611423412">Evans <italic>et al</italic>. 2009</xref>, <xref ref-type="bibr" rid="bibr41-1756285611423412">2004</xref>].</p>
<p>The neuropsychiatric outcome of bilateral STN-DBS is varied, with a broad range in reported rates of behavioural changes – depression 1.5–25%, attempted and completed suicide 0.5–2.9% and hypomania 4–15% [<xref ref-type="bibr" rid="bibr136-1756285611423412">Voon <italic>et al</italic>. 2006</xref>]. Transient confusion and hypomania following bilateral STN-DBS has been reported, with improvement over 3–6 months [<xref ref-type="bibr" rid="bibr136-1756285611423412">Voon <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr126-1756285611423412">Takeshita <italic>et al</italic>. 2005</xref>]. Depressive symptoms have been shown to improve [<xref ref-type="bibr" rid="bibr136-1756285611423412">Voon <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr126-1756285611423412">Takeshita <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr33-1756285611423412">Daniele <italic>et al</italic>. 2003</xref>], remain unchanged [<xref ref-type="bibr" rid="bibr42-1756285611423412">Fasano <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr98-1756285611423412">Porat <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr150-1756285611423412">Witt <italic>et al</italic>. 2008</xref>] or worsen [<xref ref-type="bibr" rid="bibr45-1756285611423412">Follet <italic>et al</italic>. 2010</xref>] after STN-DBS.</p>
<p>Suicide rates [<xref ref-type="bibr" rid="bibr98-1756285611423412">Porat <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr83-1756285611423412">Nazem <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr117-1756285611423412">Soulas <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr137-1756285611423412">Voon <italic>et al</italic>. 2008</xref>], anxiety, apathy [<xref ref-type="bibr" rid="bibr98-1756285611423412">Porat <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr38-1756285611423412">Drapier <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr48-1756285611423412">Funkiewiez <italic>et al</italic>. 2004</xref>] and impulsivity [<xref ref-type="bibr" rid="bibr20-1756285611423412">Bronstein <italic>et al</italic>. 2011</xref>] were found to worsen in most studies after STN-DBS. Few dopaminergic drugs are effective in improving mood in patients with PD. Pramipexole [<xref ref-type="bibr" rid="bibr11-1756285611423412">Barone <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr70-1756285611423412">Leentjens <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr102-1756285611423412">Rectorová <italic>et al</italic>. 2003</xref>], ropinirole [<xref ref-type="bibr" rid="bibr104-1756285611423412">Rektorová <italic>et al</italic>. 2008</xref>] and the newer MAO-B inhibitor safinamide [<xref ref-type="bibr" rid="bibr16-1756285611423412">Borgohain <italic>et al</italic>. 2009</xref>] improve depression, while pergolide and other MAO-B inhibitors, for example selegiline, do not have significant antidepressant activity [<xref ref-type="bibr" rid="bibr152-1756285611423412">Youdim and Bakhle, 2006</xref>].</p>
<p>Hallucinations, especially visual, and psychosis are a common complication in patients with PD. Older age, cognitive and visual disturbances can contribute to their emergence [<xref ref-type="bibr" rid="bibr97-1756285611423412">Poewe, 2003</xref>]. Hallucinations and psychosis are aggravated by all dopaminergic and anticholinergic drugs [<xref ref-type="bibr" rid="bibr97-1756285611423412">Poewe, 2003</xref>; <xref ref-type="bibr" rid="bibr86-1756285611423412">Oertel <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr94-1756285611423412">Parkinson Study Group, 2000</xref>; <xref ref-type="bibr" rid="bibr101-1756285611423412">Rascol <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr106-1756285611423412">Rinne <italic>et al</italic>. 1998</xref>]. Levodopa and dopamine agonists can cause many behavioural abnormalities such as impulse control disorders (ICDs), punding and dopamine dysregulation syndrome, which result in significant impairment in social function [<xref ref-type="bibr" rid="bibr41-1756285611423412">Evans <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr69-1756285611423412">Lawrence <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr142-1756285611423412">Weintraub <italic>et al</italic>. 2010</xref>]. A recent review on the effect of bilateral STN-DBS showed that preoperative impulse control and related disorders may resolve or improve after STN-DBS, but these can also worsen or show no change at all. Moreover STN-DBS can also reveal or induce ICDs [<xref ref-type="bibr" rid="bibr19-1756285611423412">Broen <italic>et al</italic>. 2011</xref>].</p>
<p>Studies comparing DBS and best medical treatment are shown in <xref ref-type="table" rid="table1-1756285611423412">Table 1</xref>. Most studies have shown no significant change or improvement in scores of anxiety and depression [<xref ref-type="bibr" rid="bibr139-1756285611423412">Wang <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr140-1756285611423412">Weaver <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr26-1756285611423412">Castelli <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr150-1756285611423412">Witt <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr151-1756285611423412">York <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr116-1756285611423412">Smeding <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr82-1756285611423412">Morrison <italic>et al</italic>. 2004</xref>]. Few studies have shown worsening of depression [<xref ref-type="bibr" rid="bibr123-1756285611423412">Strutt <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr35-1756285611423412">De Gasperi <italic>et al</italic>. 2006</xref>] and apathy [<xref ref-type="bibr" rid="bibr66-1756285611423412">Kirsh-Darrow <italic>et al</italic>. 2011</xref>]. A controlled study showed increased overall psychiatric complaints (9%) in 99 patients who had STN-DBS compared with 3% in 36 patients on DRT [<xref ref-type="bibr" rid="bibr116-1756285611423412">Smeding <italic>et al</italic>. 2006</xref>]. Two studies used gambling tasks to compare patients on dopaminergic agonists with patients who had STN-DBS [<xref ref-type="bibr" rid="bibr74-1756285611423412">Lulé <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr90-1756285611423412">Oyama <italic>et al</italic>. 2011</xref>]. In both studies, patients in the stimulator ‘on’ state were worse than in the ‘off’ state. Lulé and colleagues showed patients on medical treatment were worse compared with the STN-DBS group, while there was no significant difference in the study by Oyama and colleagues. This suggests that STN-DBS has a mild worsening of impulse control behaviour, but the concurrent decrease in dopaminergic medication may cause an overall reduction in impulse control abnormalities [<xref ref-type="bibr" rid="bibr74-1756285611423412">Lulé <italic>et al</italic>. 2011</xref>].</p>
<p>In a direct comparison, bilateral STN-DBS was associated with worsening and bilateral GPi-DBS with improvement of depression [<xref ref-type="bibr" rid="bibr45-1756285611423412">Follet <italic>et al</italic>. 2010</xref>]. This could be a manifestation of dopamine withdrawal syndrome and may be secondary to mesolimbic dopaminergic denervation or a direct effect of STN-DBS [<xref ref-type="bibr" rid="bibr129-1756285611423412">Thobois <italic>et al</italic>. 2010</xref>]. In another head-to-head comparison trial, STN-DBS resulted in significant reduction in dopaminergic drug dosage compared with GPi-DBS, but was associated with more neuropsychiatric impairment [<xref ref-type="bibr" rid="bibr81-1756285611423412">Moro <italic>et al</italic>. 2010</xref>].</p>
<p>Thus, overall, there may be a mild worsening of cognition and a risk of worsening of psychiatric disorders after STN-DBS. Reduction of behavioural disorders like ICDs by decreasing dopaminergic medication and other mechanisms [<xref ref-type="bibr" rid="bibr8-1756285611423412">Ardouin <italic>et al</italic>. 2006</xref>] is also seen. GPi-DBS, however, seems to cause insignificant neuropsychiatric impairments.</p>
</sec>
<sec id="section7-1756285611423412">
<title>Autonomic dysfunction</title>
<p>Autonomic dysfunction is common in patients with PD and can precede the onset of motor symptoms [<xref ref-type="bibr" rid="bibr134-1756285611423412">Visser <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr62-1756285611423412">Jost, 2003</xref>]. The association of autonomic disturbance has been recognized from the first description by James <xref ref-type="bibr" rid="bibr93-1756285611423412">Parkinson (1817)</xref> and it increases with progression of disease, causing a major impact on quality of life [<xref ref-type="bibr" rid="bibr62-1756285611423412">Jost, 2003</xref>].</p>
<p>Autonomic dysfunction in PD is thought to be predominantly due to central degeneration involving the ventrolateral medulla, dorsal motor vagal nucleus, nucleus tractus solitarius, periaqueductal gray matter in midbrain and descending sympathetic and parasympathetic pathways [<xref ref-type="bibr" rid="bibr17-1756285611423412">Braak <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr13-1756285611423412">Benarroch <italic>et al</italic>. 2000</xref>]. However, recent studies have demonstrated diffuse sympathetic denervation involving both central and peripheral neurons in patients with symptomatic autonomic disturbances [<xref ref-type="bibr" rid="bibr53-1756285611423412">Goldstein <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr89-1756285611423412">Orimo <italic>et al</italic>. 2002</xref>] and Lewy body pathology has also been found in peripheral autonomic neurons and ganglia [<xref ref-type="bibr" rid="bibr79-1756285611423412">Minguez-Castellanos <italic>et al</italic>. 2007</xref>].</p>
</sec>
<sec id="section8-1756285611423412">
<title>Cardiovascular</title>
<p>Cardiac autonomic disturbances are troublesome and especially orthostatic hypotension is a common problem. Levodopa and most antiparkinsonian medications can exacerbate orthostatic hypotension by varying levels [<xref ref-type="bibr" rid="bibr15-1756285611423412">Bhattacharya <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr76-1756285611423412">Lyytinen <italic>et al</italic>. 2001</xref>; <xref ref-type="bibr" rid="bibr68-1756285611423412">Kujawa <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr23-1756285611423412">Calne <italic>et al</italic>. 1960</xref>]. A recent Cochrane review on dopamine agonists demonstrated almost equal incidences of orthostatic hypotension with levodopa and dopamine agonists [<xref ref-type="bibr" rid="bibr122-1756285611423412">Stowe <italic>et al</italic>. 2008</xref>].</p>
<p>Experimental studies in cats have shown that stimulation of the STN and globus pallidum externa produces tachycardia [<xref ref-type="bibr" rid="bibr5-1756285611423412">Angyán, 1994</xref>] while stimulation of the GPi produces bradycardia [<xref ref-type="bibr" rid="bibr6-1756285611423412">Angyán and Angyán, 1999</xref>]. Thornton and colleagues showed similar response in humans with an increase in heart rate and mean arterial pressure on STN stimulation while GPi stimulation showed no change in cardiovascular parameters [<xref ref-type="bibr" rid="bibr130-1756285611423412">Thornton <italic>et al</italic>. 2002</xref>, <xref ref-type="bibr" rid="bibr63-1756285611423412">Kaufmann et al, 2002</xref>]. Beneditti and colleagues showed that stimulation of the dorsal STN and/or the zona incerta resulted in constant autonomic changes, suggesting that they are involved in autonomic control, whereas the ventral STN and/or the substantia nigra reticulata are involved in associative/limbic-related autonomic activity and their stimulation resulted in varying autonomic changes [<xref ref-type="bibr" rid="bibr14-1756285611423412">Beneditti <italic>et al</italic>. 2004</xref>].</p>
<p>The autonomic changes seen with STN-DBS may help in orthostatic hypotension by increasing heart rate, improving baroreceptor sensitivity and peripheral vasoconstriction, as noted by Stemper and colleagues [<xref ref-type="bibr" rid="bibr119-1756285611423412">Stemper <italic>et al</italic>. 2006</xref>]. The effect may be secondary to an increased central sympathetic stimulation. Priori and colleagues also demonstrated an alteration in visual evoked potential, somatosensory evoked potential, sympathetic skin response and plasma renin level with DBS [<xref ref-type="bibr" rid="bibr99-1756285611423412">Priori <italic>et al</italic>. 2001</xref>]. Other case series however did not find a similar change in heart rate, blood pressure and respiratory rate in patients with STN-DBS [<xref ref-type="bibr" rid="bibr39-1756285611423412">Erola <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr72-1756285611423412">Lipp <italic>et al</italic>. 2005</xref>].</p>
<p>Two controlled studies compared the effect of DRT and DBS on cardiovascular autonomic functions. Holmberg and colleagues compared 11 patients who had STN-DBS with eight patients on optimal medical therapy at baseline (preoperative) and at 1 year [<xref ref-type="bibr" rid="bibr60-1756285611423412">Holmberg <italic>et al</italic>. 2005</xref>]. There was no difference in cardiovascular autonomic dysfunction in both groups in spite of a reduction in dose of dopaminergic medication in the STN-DBS group. The numbers in the study were small and the groups were heterogeneous with significantly shorter duration of disease in the pharmacotherapy group. Thus a small significant impact of STN-DBS may have been missed. Ludwig and colleagues compared the effect of levodopa with that of STN-DBS [<xref ref-type="bibr" rid="bibr73-1756285611423412">Ludwig <italic>et al</italic>. 2007</xref>]. This was an immediate effect of a single dose of levodopa and the effect of STN-DBS compared with when it was switched off. While levodopa increased orthostatic hypotension, STN-DBS did not produce cardiovascular autonomic disturbances and only caused cutaneous vasoconstriction. The authors postulated that the effect of levodopa may have been secondary to a reduced sympathetic outflow caused by D2 receptor stimulation. The cardiovascular autonomic dysfunction in PD may be a combination of central and peripheral autonomic changes and the lack of effect of STN-DBS may stem from its inability to correct the peripheral component. An overall improvement in autonomic functions may be gained by the reduction of dopaminergic drugs after STN-DBS [<xref ref-type="bibr" rid="bibr73-1756285611423412">Ludwig <italic>et al</italic>. 2007</xref>]. Larger randomized, controlled studies are needed to confirm the role of STN-DBS in orthostatic hypotension.</p>
</sec>
<sec id="section9-1756285611423412">
<title>Genitourinary dysfunction</title>
<p>Urinary symptoms occur in 38–71% of patients with PD, the most common being nocturia, followed by urgency and frequency [<xref ref-type="bibr" rid="bibr145-1756285611423412">Winge and Fowler, 2006</xref>]. The probable mechanism may be earlier perception of bladder sensation resulting in detrusor overactivity [<xref ref-type="bibr" rid="bibr145-1756285611423412">Winge and Fowler, 2006</xref>]. This is improved by chronic DRT with a D1- and D2-receptor-mediated increase in volume at which patients recognize bladder filling [<xref ref-type="bibr" rid="bibr22-1756285611423412">Brusa <italic>et al</italic>. 2007</xref>]. This effect of DRT is unclear and unpredictable in individual patients [<xref ref-type="bibr" rid="bibr147-1756285611423412">Winge <italic>et al</italic>. 2004</xref>]. STN-DBS has been shown to have variable results. STN-DBS improves bladder symptoms with decreased detrusor hyperreflexia [<xref ref-type="bibr" rid="bibr146-1756285611423412">Winge <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr112-1756285611423412">Seif <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr44-1756285611423412">Finazzi-Agrò <italic>et al</italic>. 2003</xref>] and increased bladder capacity [<xref ref-type="bibr" rid="bibr113-1756285611423412">Shimizu <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr57-1756285611423412">Herzog <italic>et al</italic>. 2006</xref>]. Herzog and colleagues postulated that this effect may be secondary to modulation of bladder afferents and central sensory processing.</p>
<p>There are very few studies on the effect of STN-DBS on other autonomic disorders. Sexual dysfunction is common in patients with PD. Both impaired function and excessive or distorted function have been described. Excessive or distorted function most frequently occurs in men as an adverse effect of DRT [<xref ref-type="bibr" rid="bibr96-1756285611423412">Pfieffer, 2010</xref>]. Drugs have varied effects. Apomorphine, cabergoline, pergolide and levodopa have been shown to improve sexual impairment [<xref ref-type="bibr" rid="bibr110-1756285611423412">Sakakibara <italic>et al</italic>. 2010</xref>]. Dopamine agonists can cause hypersexuality [<xref ref-type="bibr" rid="bibr67-1756285611423412">Klos <italic>et al</italic>. 2005</xref>]. STN-DBS has been shown to improve sexual wellbeing in a cohort of 31 patients 9–12 months after surgery [<xref ref-type="bibr" rid="bibr24-1756285611423412">Castelli <italic>et al</italic>. 2004</xref>] with a few reports of hypersexuality, especially in patients with mania [<xref ref-type="bibr" rid="bibr107-1756285611423412">Roane <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr108-1756285611423412">Romito <italic>et al</italic>. 2002</xref>].</p>
</sec>
<sec id="section10-1756285611423412">
<title>Gastrointestinal dysfunction</title>
<p>Chronic constipation, nausea, dribbling of saliva, vomiting, dyspepsia, gastroparesis and dysphagia are very common, seen in 80% of patients with PD [<xref ref-type="bibr" rid="bibr88-1756285611423412">Olanow <italic>et al</italic>. 2009</xref>]. A recent meta-analysis noted an increase in gastrointestinal symptoms of nausea, vomiting, dry mouth and constipation with adjuvant DRT compared with levodopa [<xref ref-type="bibr" rid="bibr121-1756285611423412">Stowe <italic>et al</italic>. 2011</xref>]. Levodopa augmented rectal contraction, lessened paradoxical sphincter contraction and reduced constipation in a group of 19 patients [<xref ref-type="bibr" rid="bibr127-1756285611423412">Tateno <italic>et al</italic>. 2011</xref>]. Improvement in constipation, excessive salivation and deglutition after STN-DBS has been noted in two studies [<xref ref-type="bibr" rid="bibr30-1756285611423412">Ciucci <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr155-1756285611423412">Zibetti <italic>et al</italic>. 2007</xref>].</p>
</sec>
<sec id="section11-1756285611423412">
<title>Thermoregulation and sweating</title>
<p>Thermoregulation is impaired in patients with PD and sweating abnormalities can be troublesome. Abnormal sensations of heat or cold, impaired sweating responses, and hypothermia can all occur [<xref ref-type="bibr" rid="bibr88-1756285611423412">Olanow <italic>et al</italic>. 2009</xref>]. In a study done by Swinn and colleagues, thermoregulatory abnormalities were found in 64% of patients with PD compared with only 12% of controls [<xref ref-type="bibr" rid="bibr124-1756285611423412">Swinn <italic>et al</italic>. 2003</xref>]. Severe drenching sweats occur commonly as an end-of-dose ‘off’ phenomenon in patients with advanced disease and these may be satisfactorily controlled with adequate DRT [<xref ref-type="bibr" rid="bibr100-1756285611423412">Pursiannen <italic>et al</italic>. 2007</xref>]. STN-DBS has been reported to ameliorate sweating during ‘off’ periods in patients with by 66%, 6 months after surgery [<xref ref-type="bibr" rid="bibr131-1756285611423412">Trachani <italic>et al</italic>. 2010</xref>] and markedly reduce the fluctuations [<xref ref-type="bibr" rid="bibr149-1756285611423412">Witjas <italic>et al</italic>. 2007</xref>]. The effect of DBS on sweating abnormalities occurring during the dopaminergic drug ‘on’ state has not been studied as yet.</p>
<p>Based on the current literature, STN-DBS may have a positive effect on cardiovascular autonomic disturbances and may improve orthostatic hypotension through reduction of DRT. There is some suggestion that STN-DBS may improve gastrointestinal, genitourinary and thermoregulatory symptoms more than medical therapy, but controlled studies are required.</p>
</sec>
</sec>
<sec id="section12-1756285611423412">
<title>Sleep</title>
<p>Sleep disturbances affect 74–98% of patients with PD [<xref ref-type="bibr" rid="bibr4-1756285611423412">Amara <italic>et al</italic>. 2011</xref>]. These include insomnia, sleep fragmentation with early morning wakening, excessive daytime sleepiness, sleep attacks, rapid eye movement sleep behavioural disorder, nightmares and parasomnias, restless legs syndrome, periodic limb movements of sleep and akathisia [<xref ref-type="bibr" rid="bibr4-1756285611423412">Amara <italic>et al</italic>. 2011</xref>]. Sleep disturbances in patients with PD are multifactorial. Degeneration of dopaminergic and nondopaminergic neurons in the brainstem causing specific sleep disorders, parkinsonian motor dysfunction, dyskinesias, pain, nocturia, dopaminergic and nondopaminergic medications, all contribute to sleep disturbances [<xref ref-type="bibr" rid="bibr88-1756285611423412">Olanow <italic>et al</italic>. 2009</xref>]. In a recent study, the severity of sleep disturbance correlated positively with disease severity, UPDRS motor scores, levodopa dose, severity of rigidity, and severity of bradykinesia [<xref ref-type="bibr" rid="bibr156-1756285611423412">Ziemssen and Reichmann, 2007</xref>].</p>
<p>Drugs have a complex effect on sleep disorders. They improve sleep disorders by improving nocturnal mobility and quality of sleep [<xref ref-type="bibr" rid="bibr92-1756285611423412">Pahwa <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr80-1756285611423412">Morgan and Sethi, 2006</xref>; <xref ref-type="bibr" rid="bibr105-1756285611423412">Reuter <italic>et al</italic>. 1999</xref>; <xref ref-type="bibr" rid="bibr10-1756285611423412">Askenasy and Yahr, 1985</xref>]. Dopaminergic agonists are also the treatment of choice for restless legs syndrome, and dramatic benefits have been observed with bedtime doses of numerous dopamine agonists, including pergolide, pramipexole, ropinirole, cabergoline and rotigotine [<xref ref-type="bibr" rid="bibr133-1756285611423412">Vignatelli <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr148-1756285611423412">Winkelman <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr120-1756285611423412">Stiasny-Kolster <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr138-1756285611423412">Walters <italic>et al</italic>. 2004</xref>]. However, at higher doses dopaminergic drugs, including levodopa and dopaminergic agonists, can cause sleep fragmentation and daytime somnolence, resulting in sleep attacks and injuries, and worsening restless legs syndrome by augmentation [<xref ref-type="bibr" rid="bibr88-1756285611423412">Olanow <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr78-1756285611423412">Micallef <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr43-1756285611423412">Ferreira <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr111-1756285611423412">Schapira, 2000</xref>; <xref ref-type="bibr" rid="bibr47-1756285611423412">Frucht <italic>et al</italic>.1999</xref>; <xref ref-type="bibr" rid="bibr3-1756285611423412">Allen and Earley, 1996</xref>].</p>
<p>Bilateral STN DBS-has been found to improve both objective polysomnographic measures of sleep and subjective sleep quality in several studies. Decreased awake state after sleep onset, improved nocturnal mobility, improvement in restless legs syndrome, increased continuous sleep time and sleep efficiency were seen after bilateral STN-DBS [<xref ref-type="bibr" rid="bibr28-1756285611423412">Chahine <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr155-1756285611423412">Zibetti <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr29-1756285611423412">Cicolin <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr9-1756285611423412">Arnulf <italic>et al</italic>. 2000</xref>]. The improvement in total sleep time, patient-reported sleep problems and early morning dystonia was seen even at 24 months after bilateral STN-DBS [<xref ref-type="bibr" rid="bibr75-1756285611423412">Lyons and Pahwa, 2006</xref>]. However, excessive daytime somnolence did not improve with bilateral STN-DBS [<xref ref-type="bibr" rid="bibr75-1756285611423412">Lyons and Pahwa, 2006</xref>]. The effect of GPi-DBS on sleep has not been well elucidated. In a recent comparative study, subjective improvement in sleep was noted in patients who underwent bilateral GPi-DBS at 36 months post surgery that was comparable to those who had bilateral STN-DBS [<xref ref-type="bibr" rid="bibr135-1756285611423412">Volkmann <italic>et al</italic>. 2009</xref>].</p>
<p>Hjort and colleagues compared the effect on sleep of 3 months of STN-DBS in 10 patients with medical treatment in 10 patients using a visual analogue scale – Parkinson’s disease sleep scale [<xref ref-type="bibr" rid="bibr59-1756285611423412">Hjort <italic>et al</italic>. 2004</xref>]. There was significant improvement in nocturnal motor symptoms and overall sleep quality while there was no effect on nocturia, sleep fragmentation and excessive daytime sleepiness. This suggests that STN-DBS probably acts only by reducing motor symptoms and does not have a significant central sleep modulation [<xref ref-type="bibr" rid="bibr59-1756285611423412">Hjort <italic>et al</italic>. 2004</xref>].</p>
</sec>
<sec id="section13-1756285611423412">
<title>Sensory changes</title>
<p>Olfactory loss is one of the first symptoms to appear in PD [<xref ref-type="bibr" rid="bibr88-1756285611423412">Olanow <italic>et al</italic>.2009</xref>]. In a cohort of 15 patients, odour identification improved significantly at 6 and 12 months after STN-DBS [<xref ref-type="bibr" rid="bibr54-1756285611423412">Guo <italic>et al</italic>. 2008</xref>]. This improvement was noted in the stimulator ‘on’ state only. STN-DBS improves neuronal activity in striatum and the orbitofrontal cortex and may result in olfactory recovery [<xref ref-type="bibr" rid="bibr54-1756285611423412">Guo <italic>et al</italic>. 2008</xref>].</p>
<p>There is a change in sensory perception in patients with PD. Pain is a common complaint, detected in 70–80% of patients [<xref ref-type="bibr" rid="bibr12-1756285611423412">Beiske <italic>et al</italic>. 2009</xref>] and is worse in the ‘off’ state [<xref ref-type="bibr" rid="bibr85-1756285611423412">Nebe and Ebersbach, 2009</xref>]. Other sensory symptoms such as numbness, itching, tingling or thermal sensations are also seen, though less frequently than pain [<xref ref-type="bibr" rid="bibr50-1756285611423412">Gierthmühlen <italic>et al</italic>. 2010</xref>].</p>
<p>Levodopa has been shown to improve sensory symptoms by the increasing pain threshold [<xref ref-type="bibr" rid="bibr49-1756285611423412">Gerdelat-Mas <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr114-1756285611423412">Slaoui <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr18-1756285611423412">Brefel-Courbon <italic>et al</italic>. 2005</xref>]. Similarly, STN-DBS has been shown to reduce pain intensity and improve pain/sensory fluctuations and nonspecific sensory complaints compared with the preoperative state in various studies [<xref ref-type="bibr" rid="bibr50-1756285611423412">Gierthmühlen <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr64-1756285611423412">Kim <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr149-1756285611423412">Witjas <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr155-1756285611423412">Zibetti <italic>et al</italic>. 2007</xref>]. Improvement in thermal threshold has been demonstrated in a recent study after DBS [<xref ref-type="bibr" rid="bibr77-1756285611423412">Maruo <italic>et al</italic>. 2011</xref>]. There are no head-to-head comparison trials of DBS and best medical treatment in sensory modulation. A recent trial compared the effect of levodopa with the stimulator in the ‘off’ state and the stimulator in the ‘on’ state in 15 patients, 6 months after STN-DBS [<xref ref-type="bibr" rid="bibr50-1756285611423412">Gierthmühlen <italic>et al</italic>. 2010</xref>]. Patients subjectively felt that pain responded to levodopa and had reduced intensity of pain after STN-DBS compared with before STN-DBS. Both STN-DBS and levodopa had no effect on objective pain sensitivity. On evaluation of temperature, STN-DBS improved thermal detection thresholds while levodopa had no effect.</p>
<p>To summarize, both levodopa and STN-DBS improve pain perception and reduce pain intensity. STN-DBS also improves olfaction and thermal detection thresholds compared with medication. There is a need for large controlled trials to verify the actual effects.</p>
</sec>
</sec>
<sec id="section14-1756285611423412">
<title>Overall nonmotor symptoms</title>
<p>The literature is scant about the effect of medication or DBS on overall score of all nonmotor symptoms in patients with PD (<xref ref-type="table" rid="table3-1756285611423412">Table 3</xref>). A small study did not find any significant effect of DRT on overall nonmotor symptom score [<xref ref-type="bibr" rid="bibr65-1756285611423412">Kim <italic>et al</italic>. 2009</xref>]. But the study was done on <italic>de novo</italic> detected patients with PD and the effect of DRT on nonmotor symptoms may be more evident later in the course. Two recent studies assessed the effect of STN-DBS on nonmotor fluctuations using comprehensive scales, including cognitive, behavioural, dysautonomic and sensory symptoms before and a year after surgery [<xref ref-type="bibr" rid="bibr84-1756285611423412">Nazarro <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr149-1756285611423412">Witjas <italic>et al</italic>. 2007</xref>]. Nazarro and colleagues demonstrated an improvement in Nonmotor Symptoms Assessment Scale score, with the best improvement in autonomic functions. Witjas and colleagues studied the effect of DBS on nonmotor fluctuations. Pain and sensory fluctuations showed the best response to STN-DBS (84.2%). A good response was noted in dysautonomic and cognitive fluctuations (60%) along with a marked reduction in the incapacitating symptoms of drenching sweats and akathisia [<xref ref-type="bibr" rid="bibr149-1756285611423412">Witjas <italic>et al</italic>. 2007</xref>].</p>
<p>Nonmotor symptoms affect patients’ quality of life. The final impact of treatment can be measured using health-related quality of life (HRQoL) scales. The scales take into account both motor and nonmotor improvements. Two randomized trials compared the effects of DRT and DBS on HRQoL using the 39-item Parkinson’s Disease Questionnaire as a primary endpoint [<xref ref-type="bibr" rid="bibr143-1756285611423412">Williams <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr37-1756285611423412">Deuschl <italic>et al</italic>. 2006</xref>]. There was a significantly better outcome in the DBS group at the end of 6 months [<xref ref-type="bibr" rid="bibr37-1756285611423412">Deuschl <italic>et al</italic>. 2006</xref>] and 12 months [<xref ref-type="bibr" rid="bibr143-1756285611423412">Williams <italic>et al</italic>. 2010</xref>]. There was significantly increased improvement in domains of mobility, activities of daily living, stigma and bodily discomfort in both studies, while improvement in emotional wellbeing was noted by Deuschl and colleagues. There was no difference in the domains of cognition, communication and social support between the two groups.</p>
<p>Further research on the effect of pharmacological therapy or DBS on nonmotor symptoms in patients with PD can help us to understand the pathophysiology of the disease and treat patients with a holistic approach.</p>
</sec>
<sec id="section15-1756285611423412" sec-type="conclusions">
<title>Conclusions</title>
<p>Nonmotor symptoms occur throughout the course of PD. Bilateral STN-DBS or GPi-DBS as well as DRT have significant effects on nonmotor symptoms. On comparing DRT with DBS, the latter is more effective in reducing sensory, sleep, gastrointestinal and urological symptoms. Bilateral STN-DBS or GPi-DBS have varying effects on cognitive, behavioural and cardiovascular autonomic disturbances, with mild worsening in cognition noted with STN-DBS. STN-DBS may have a beneficial effect on cardiovascular autonomic and some behavioural disorders by decreasing the dopaminergic dose in patients. Considering the effect of DBS on both motor and nonmotor symptoms, surgery is a safe and highly effective therapy in selected patients. As the motor effects of STN-DBS and GPi-DBS are similar, nonmotor symptoms may determine the target choice in surgery of future patients.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<p>The authors declare no conflicts of interest in preparing this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aarsland</surname><given-names>D.</given-names></name>
<name><surname>Larsen</surname><given-names>J.P.</given-names></name>
<name><surname>Lim</surname><given-names>N.G.</given-names></name>
<name><surname>Janvin</surname><given-names>C.</given-names></name>
<name><surname>Karlsen</surname><given-names>K.</given-names></name>
<name><surname>Tandberg</surname><given-names>E.</given-names></name>
<etal/>
</person-group> (<year>1999</year>) <article-title>Range of neuropsychiatric disturbances in patients with Parkinson’s disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>67</volume>: <fpage>492</fpage>–<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr2-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alberts</surname><given-names>J.L.</given-names></name>
<name><surname>Voelcker-Rehage</surname><given-names>C.</given-names></name>
<name><surname>Hallahan</surname><given-names>K.</given-names></name>
<name><surname>Vitek</surname><given-names>M.</given-names></name>
<name><surname>Bamzai</surname><given-names>R.</given-names></name>
<name><surname>Vitek</surname><given-names>J.L.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Bilateral subthalamic stimulation impairs cognitive-motor performance in Parkinson’s disease patients</article-title>. <source>Brain</source> <volume>131</volume>: <fpage>3348</fpage>–<lpage>3360</lpage>.</citation>
</ref>
<ref id="bibr3-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allen</surname><given-names>R.P.</given-names></name>
<name><surname>Earley</surname><given-names>C.J.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Augmentation of the restless legs syndrome with carbidopa/levodopa</article-title>. <source>Sleep</source> <volume>19</volume>: <fpage>205</fpage>–<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr4-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amara</surname><given-names>A.W.</given-names></name>
<name><surname>Watts</surname><given-names>R.L.</given-names></name>
<name><surname>Walker</surname><given-names>H.C.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The effects of deep brain stimulation on sleep in Parkinson’s disease</article-title>. <source>Ther Adv Neurol Disord</source> <volume>4</volume>: <fpage>15</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr5-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Angyán</surname><given-names>L.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Somatomotor and cardiorespiratory responses to basal ganglia stimulation in cats</article-title>. <source>Physiol Behav</source> <volume>56</volume>: <fpage>167</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr6-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Angyán</surname><given-names>L.</given-names></name>
<name><surname>Angyán</surname><given-names>Z.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Characterization of cardiorespiratory responses to electrical stimulation of the globus pallidus in cat</article-title>. <source>Physiol Behav</source> <volume>66</volume>: <fpage>1953</fpage>–<lpage>1958</lpage>.</citation>
</ref>
<ref id="bibr7-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Antonini</surname><given-names>A.</given-names></name>
<name><surname>Isaias</surname><given-names>I.U.</given-names></name>
<name><surname>Rodolfi</surname><given-names>G.</given-names></name>
<name><surname>Landi</surname><given-names>A.</given-names></name>
<name><surname>Natuzzi</surname><given-names>F.</given-names></name>
<name><surname>Siri</surname><given-names>C.</given-names></name>
<etal/>
</person-group> (<year>2011</year>) <article-title>A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation</article-title>. <source>J Neurol</source> <volume>258</volume>: <fpage>579</fpage>–<lpage>585</lpage>.</citation>
</ref>
<ref id="bibr8-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ardouin</surname><given-names>C.</given-names></name>
<name><surname>Voon</surname><given-names>V.</given-names></name>
<name><surname>Worbe</surname><given-names>Y.</given-names></name>
<name><surname>Abouazar</surname><given-names>N.</given-names></name>
<name><surname>Czernecki</surname><given-names>V.</given-names></name>
<name><surname>Hosseini</surname><given-names>H.</given-names></name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Pathological gambling in Parkinson’s disease improves on chronic subthalamic nucleus stimulation</article-title>. <source>Mov Disord</source> <volume>21</volume>: <fpage>1941</fpage>–<lpage>1946</lpage>.</citation>
</ref>
<ref id="bibr9-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnulf</surname><given-names>I.</given-names></name>
<name><surname>Bejjani</surname><given-names>B.P.</given-names></name>
<name><surname>Garma</surname><given-names>L.</given-names></name>
<name><surname>Bonnet</surname><given-names>A.M.</given-names></name>
<name><surname>Houeto</surname><given-names>J.L.</given-names></name>
<name><surname>Damier</surname><given-names>P.</given-names></name>
<etal/>
</person-group> (<year>2000</year>) <article-title>Improvement of sleep architecture in PD with subthalamic nucleus stimulation</article-title>. <source>Neurology</source> <volume>55</volume>: <fpage>1732</fpage>–<lpage>1734</lpage>.</citation>
</ref>
<ref id="bibr10-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Askenasy</surname><given-names>J.J.M.</given-names></name>
<name><surname>Yahr</surname><given-names>M.D.</given-names></name>
</person-group> (<year>1985</year>) <article-title>Reversal of sleep disturbance in Parkinson’s disease by antiparkinsonianian therapy: a preliminary study</article-title>. <source>Neurology</source> <volume>35</volume>: <fpage>527</fpage>–<lpage>532</lpage>.</citation>
</ref>
<ref id="bibr11-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barone</surname><given-names>P.</given-names></name>
<name><surname>Poewe</surname><given-names>W.</given-names></name>
<name><surname>Albrecht</surname><given-names>S.</given-names></name>
<name><surname>Debieuvre</surname><given-names>C.</given-names></name>
<name><surname>Massey</surname><given-names>D.</given-names></name>
<name><surname>Rascol</surname><given-names>O.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet Neurol</source> <volume>9</volume>: <fpage>573</fpage>–<lpage>580</lpage>.</citation>
</ref>
<ref id="bibr12-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beiske</surname><given-names>A.G.</given-names></name>
<name><surname>Loge</surname><given-names>J.H.</given-names></name>
<name><surname>Rønningen</surname><given-names>A.</given-names></name>
<name><surname>Svensson</surname><given-names>E.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Pain in Parkinson’s disease: prevalence and characteristics</article-title>. <source>Pain</source> <volume>141</volume>: <fpage>173</fpage>–<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr13-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benarroch</surname><given-names>E.E.</given-names></name>
<name><surname>Schmeichel</surname><given-names>A.M.</given-names></name>
<name><surname>Parisi</surname><given-names>J.E.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Involvement of the ventrolateral medulla in parkinsonism with autonomic failure</article-title>. <source>Neurology</source> <volume>54</volume>: <fpage>963</fpage>–<lpage>968</lpage>.</citation>
</ref>
<ref id="bibr14-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beneditti</surname><given-names>F.</given-names></name>
<name><surname>Colloca</surname><given-names>L.</given-names></name>
<name><surname>Lanotte</surname><given-names>M.</given-names></name>
<name><surname>Bergamasco</surname><given-names>B.</given-names></name>
<name><surname>Torre</surname><given-names>E.</given-names></name>
<name><surname>Lopiano</surname><given-names>L.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Autonomic and emotional responses to open and hidden stimulations of the human subthalamic region</article-title>. <source>Brain Res Bull</source> <volume>63</volume>: <fpage>203</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr15-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhattacharya</surname><given-names>K.F.</given-names></name>
<name><surname>Nouri</surname><given-names>S.</given-names></name>
<name><surname>Olanow</surname><given-names>C.W.</given-names></name>
<name><surname>Yahr</surname><given-names>M.D.</given-names></name>
<name><surname>Kaufmann</surname><given-names>H.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Selegiline in the treatment of Parkinson’s disease: its impact on orthostatic hypotension</article-title>. <source>Parkinsonism Relat Disord</source> <volume>9</volume>: <fpage>221</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr16-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Borgohain</surname><given-names>R.</given-names></name>
<name><surname>Mehta</surname><given-names>N.A.</given-names></name>
<name><surname>Bajenaru</surname><given-names>O.A.</given-names></name>
<name><surname>Quatrale</surname><given-names>R.</given-names></name>
<name><surname>Lucini</surname><given-names>V.</given-names></name>
<name><surname>Anand</surname><given-names>R.</given-names></name>
<etal/>
</person-group> <collab>The Study 016 Investigators</collab>. (<year>2009</year>) <article-title>Effect of safinamide on depressive symptoms in patients with mid-late stage Parkinson’s disease. Abstracts of the Fourteenth International Congress of Parkinson’s Disease and Movement Disorders</article-title>. <source>Mov Disord</source> <volume>25</volume>: <fpage>S181</fpage>–<lpage>S565</lpage>.</citation>
</ref>
<ref id="bibr17-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braak</surname><given-names>H.</given-names></name>
<name><surname>Ghebremedhin</surname><given-names>E.</given-names></name>
<name><surname>Rüb</surname><given-names>U.</given-names></name>
<name><surname>Bratzke</surname><given-names>H.</given-names></name>
<name><surname>Del Tredici</surname><given-names>K.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Stages in the development of Parkinson’s disease-related pathology</article-title>. <source>Cell Tissue Res</source> <volume>318</volume>: <fpage>121</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr18-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brefel-Courbon</surname><given-names>C.</given-names></name>
<name><surname>Payoux</surname><given-names>P.</given-names></name>
<name><surname>Thalamas</surname><given-names>C.</given-names></name>
<name><surname>Ory-Magne</surname><given-names>F.</given-names></name>
<name><surname>Slaoui</surname><given-names>T.</given-names></name>
<name><surname>Rascol</surname><given-names>O.</given-names></name>
<etal/>
</person-group> (<year>2005</year>) <article-title>Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study</article-title>. <source>Mov Disord</source> <volume>20</volume>: <fpage>1557</fpage>–<lpage>1563</lpage>.</citation>
</ref>
<ref id="bibr19-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Broen</surname><given-names>M.</given-names></name>
<name><surname>Duits</surname><given-names>A.</given-names></name>
<name><surname>Visser-Vandewalle</surname><given-names>V.</given-names></name>
<name><surname>Temel</surname><given-names>Y.</given-names></name>
<name><surname>Winogrodzka</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Impulse control and related disorders in Parkinson’s disease patients treated with bilateral subthalamic nucleus stimulation: a review</article-title>. <source>Parkinsonism Relat Disord</source> <volume>17</volume>: <fpage>413</fpage>–<lpage>417</lpage>.</citation>
</ref>
<ref id="bibr20-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bronstein</surname><given-names>J.M.</given-names></name>
<name><surname>Tagliati</surname><given-names>M.</given-names></name>
<name><surname>Alterman</surname><given-names>R.L.</given-names></name>
<name><surname>Lozano</surname><given-names>A.M.</given-names></name>
<name><surname>Volkmann</surname><given-names>J.</given-names></name>
<name><surname>Stefani</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2011</year>) <article-title>Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues</article-title>. <source>Arch Neurol</source> <volume>68</volume>: <fpage>165</fpage>.</citation>
</ref>
<ref id="bibr21-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brusa</surname><given-names>L.</given-names></name>
<name><surname>Bassi</surname><given-names>A.</given-names></name>
<name><surname>Stefani</surname><given-names>A.</given-names></name>
<name><surname>Pierantozzi</surname><given-names>M.</given-names></name>
<name><surname>Peppe</surname><given-names>A.</given-names></name>
<name><surname>Caramia</surname><given-names>M.D.</given-names></name>
<etal/>
</person-group> (<year>2003</year>) <article-title>Pramipexole in comparison to l-dopa: a neuropsychological study</article-title>. <source>J Neural Transm</source> <volume>110</volume>: <fpage>373</fpage>–<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr22-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brusa</surname><given-names>L.</given-names></name>
<name><surname>Petta</surname><given-names>F.</given-names></name>
<name><surname>Pisani</surname><given-names>A.</given-names></name>
<name><surname>Moschella</surname><given-names>V.</given-names></name>
<name><surname>Iani</surname><given-names>C.</given-names></name>
<name><surname>Stanzione</surname><given-names>P.</given-names></name>
<etal/>
</person-group> (<year>2007</year>) <article-title>Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease</article-title>. <source>Neurology</source> <volume>68</volume>: <fpage>1455</fpage>–<lpage>1459</lpage>.</citation>
</ref>
<ref id="bibr23-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calne</surname><given-names>D.B.</given-names></name>
<name><surname>Brennan</surname><given-names>J.</given-names></name>
<name><surname>Spiers</surname><given-names>A.S.D.</given-names></name>
<name><surname>Stern</surname><given-names>G.M.</given-names></name>
</person-group> (<year>1960</year>) <article-title>Hypotension caused by L-dopa</article-title>. <source>BMJ</source> <volume>1</volume>: <fpage>474</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr24-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Castelli</surname><given-names>L.</given-names></name>
<name><surname>Perozzo</surname><given-names>P.</given-names></name>
<name><surname>Genesia</surname><given-names>M.L.</given-names></name>
<name><surname>Torre</surname><given-names>E.</given-names></name>
<name><surname>Pesare</surname><given-names>M.</given-names></name>
<name><surname>Cinquepalmi</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2004</year>) <article-title>Sexual well being in parkinsonian patients after deep brain stimulation of the subthalamic nucleus</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>75</volume>: <fpage>1260</fpage>–<lpage>1264</lpage>.</citation>
</ref>
<ref id="bibr25-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Castelli</surname><given-names>L.</given-names></name>
<name><surname>Rizzi</surname><given-names>L.</given-names></name>
<name><surname>Zibetti</surname><given-names>M.</given-names></name>
<name><surname>Angrisano</surname><given-names>S.</given-names></name>
<name><surname>Lanotte</surname><given-names>M.</given-names></name>
<name><surname>Lopiano</surname><given-names>L.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Neuropsychological changes 1-year after subthalamic DBS in PD patients: a prospective controlled study</article-title>. <source>Parkinsonism Relat Disord</source> <volume>16</volume>: <fpage>115</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr26-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Castelli</surname><given-names>L.</given-names></name>
<name><surname>Zibetti</surname><given-names>M.</given-names></name>
<name><surname>Rizzi</surname><given-names>L.</given-names></name>
<name><surname>Caglio</surname><given-names>M.</given-names></name>
<name><surname>Lanotte</surname><given-names>M.</given-names></name>
<name><surname>Lopiano</surname><given-names>L.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Neuropsychiatric symptoms three years after subthalamic DBS in PD patients: a case-control study</article-title>. <source>J Neurol</source> <volume>255</volume>: <fpage>1515</fpage>–<lpage>1520</lpage>.</citation>
</ref>
<ref id="bibr27-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Castner</surname><given-names>J.E.</given-names></name>
<name><surname>Chenery</surname><given-names>H.J.</given-names></name>
<name><surname>Silburn</surname><given-names>P.A.</given-names></name>
<name><surname>Coyne</surname><given-names>T.J.</given-names></name>
<name><surname>Sinclair</surname><given-names>F.</given-names></name>
<name><surname>Smith</surname><given-names>E.R.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Effects of subthalamic deep brain stimulation on noun/verb generation and selection from competing alternatives in Parkinson’s disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>79</volume>: <fpage>700</fpage>–<lpage>705</lpage>.</citation>
</ref>
<ref id="bibr28-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chahine</surname><given-names>L.M.</given-names></name>
<name><surname>Ahmed</surname><given-names>A.</given-names></name>
<name><surname>Sun</surname><given-names>Z.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Effects of STN DBS for Parkinson’s disease on restless legs syndrome and other sleep-related measures</article-title>. <source>Parkinsonism Relat Disord</source> <volume>17</volume>: <fpage>208</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr29-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cicolin</surname><given-names>A.</given-names></name>
<name><surname>Lopiano</surname><given-names>L.</given-names></name>
<name><surname>Zibetti</surname><given-names>M.</given-names></name>
<name><surname>Torre</surname><given-names>E.</given-names></name>
<name><surname>Tavella</surname><given-names>A.</given-names></name>
<name><surname>Guastamacchia</surname><given-names>G.</given-names></name>
<etal/>
</person-group> (<year>2004</year>) <article-title>Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients</article-title>. <source>Sleep Med</source> <volume>5</volume>: <fpage>207</fpage>–<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr30-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ciucci</surname><given-names>M.R.</given-names></name>
<name><surname>Barkmeier-Kraemer</surname><given-names>J.M.</given-names></name>
<name><surname>Sherman</surname><given-names>S.J.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Subthalamic nucleus deep brain stimulation improves deglutition in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>23</volume>: <fpage>676</fpage>–<lpage>683</lpage>.</citation>
</ref>
<ref id="bibr31-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Comella</surname><given-names>C.L.</given-names></name>
<name><surname>Morrissey</surname><given-names>M.</given-names></name>
<name><surname>Janko</surname><given-names>K.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy</article-title>. <source>Neurology</source> <volume>64</volume>: <fpage>1450</fpage>–<lpage>1451</lpage>.</citation>
</ref>
<ref id="bibr32-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Costa</surname><given-names>A.</given-names></name>
<name><surname>Peppe</surname><given-names>A.</given-names></name>
<name><surname>Dell’Agnello</surname><given-names>G.</given-names></name>
<name><surname>Carlesimo</surname><given-names>G.A.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Dopamine and cognitive functioning in de novo subjects with Parkinson’s disease: effects of pramipexole and pergolide on working memory</article-title>. <source>Neuropsychologia</source> <volume>47</volume>: <fpage>1374</fpage>–<lpage>1381</lpage>.</citation>
</ref>
<ref id="bibr33-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Daniele</surname><given-names>A.</given-names></name>
<name><surname>Albanese</surname><given-names>A.</given-names></name>
<name><surname>Contarino</surname><given-names>M.F.</given-names></name>
<name><surname>Zinzi</surname><given-names>P.</given-names></name>
<name><surname>Barbier</surname><given-names>A.</given-names></name>
<name><surname>Gasparini</surname><given-names>F.</given-names></name>
<etal/>
</person-group> (<year>2003</year>) <article-title>Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson’s disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>74</volume>: <fpage>175</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr34-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Daniels</surname><given-names>C.</given-names></name>
<name><surname>Krack</surname><given-names>P.</given-names></name>
<name><surname>Volkmann</surname><given-names>J.</given-names></name>
<name><surname>Pinsker</surname><given-names>M.O.</given-names></name>
<name><surname>Krause</surname><given-names>M.</given-names></name>
<name><surname>Tronnier</surname><given-names>V.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>25</volume>: <fpage>1583</fpage>–<lpage>1589</lpage>.</citation>
</ref>
<ref id="bibr35-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Gaspari</surname><given-names>D.</given-names></name>
<name><surname>Siri</surname><given-names>C.</given-names></name>
<name><surname>Landi</surname><given-names>A.</given-names></name>
<name><surname>Cilia</surname><given-names>R.</given-names></name>
<name><surname>Bonetti</surname><given-names>A.</given-names></name>
<name><surname>Natuzzi</surname><given-names>F.</given-names></name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>77</volume>: <fpage>450</fpage>–<lpage>453</lpage>.</citation>
</ref>
<ref id="bibr36-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dellapina</surname><given-names>E.</given-names></name>
<name><surname>Gerdelat-Mas</surname><given-names>A.</given-names></name>
<name><surname>Ory-Magne</surname><given-names>F.</given-names></name>
<name><surname>Pourcel</surname><given-names>L.</given-names></name>
<name><surname>Galitzky</surname><given-names>M.</given-names></name>
<name><surname>Calvas</surname><given-names>F.</given-names></name>
<etal/>
</person-group> (<year>2011</year>) <article-title>Apomorphine effect on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study</article-title>. <source>Mov Disord</source> <volume>26</volume>: <fpage>153</fpage>–<lpage>157</lpage>.</citation>
</ref>
<ref id="bibr37-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deuschl</surname><given-names>G.</given-names></name>
<name><surname>Schade-Brittinger</surname><given-names>C.</given-names></name>
<name><surname>Krack</surname><given-names>P.</given-names></name>
<name><surname>Volkmann</surname><given-names>J.</given-names></name>
<name><surname>Schäfer</surname><given-names>H.</given-names></name>
<name><surname>Bötzel</surname><given-names>K.</given-names></name>
<etal/>
</person-group> (<year>2006</year>) <article-title>German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson’s disease</article-title>. <source>N Engl J Med</source> <volume>355</volume>: <fpage>896</fpage>–<lpage>908</lpage>.</citation>
</ref>
<ref id="bibr38-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drapier</surname><given-names>D.</given-names></name>
<name><surname>Drapier</surname><given-names>S.</given-names></name>
<name><surname>Sauleau</surname><given-names>P.</given-names></name>
<name><surname>Haegelen</surname><given-names>C.</given-names></name>
<name><surname>Raoul</surname><given-names>S.</given-names></name>
<name><surname>Biseul</surname><given-names>I.</given-names></name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Does subthalamic nucleus stimulation induce apathy in Parkinson’s disease?</article-title>. <source>J Neurol</source> <volume>253</volume>: <fpage>1081</fpage>–<lpage>1093</lpage>.</citation>
</ref>
<ref id="bibr39-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Erola</surname><given-names>T.</given-names></name>
<name><surname>Haapaniemi</surname><given-names>T.</given-names></name>
<name><surname>Heikkinen</surname><given-names>E.</given-names></name>
<name><surname>Huikuri</surname><given-names>H.</given-names></name>
<name><surname>Myllyä</surname><given-names>V.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Subthalamic nucleus deep brain stimulation does not alter long-term heart rate variability in Parkinson’s disease</article-title>. <source>Clin Auton Res</source> <volume>16</volume>: <fpage>286</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr40-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Evans</surname><given-names>A.H.</given-names></name>
<name><surname>Lees</surname><given-names>A.J.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Dopamine dysregulation syndrome in Parkinson’s disease</article-title>. <source>Curr Opin Neurol</source> <volume>17</volume>: <fpage>393</fpage>–<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr41-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Evans</surname><given-names>A.H.</given-names></name>
<name><surname>Strafella</surname><given-names>A.P.</given-names></name>
<name><surname>Weintraub</surname><given-names>D.</given-names></name>
<name><surname>Stacy</surname><given-names>M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Impulsive and compulsive behaviors in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>24</volume>: <fpage>1561</fpage>–<lpage>1570</lpage>.</citation>
</ref>
<ref id="bibr42-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fasano</surname><given-names>A.</given-names></name>
<name><surname>Romito</surname><given-names>L.M.</given-names></name>
<name><surname>Daniele</surname><given-names>A.</given-names></name>
<name><surname>Piano</surname><given-names>C.</given-names></name>
<name><surname>Zinno</surname><given-names>M.</given-names></name>
<name><surname>Bentivoglio</surname><given-names>A.R.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants</article-title>. <source>Brain</source> <volume>133</volume>(<issue>9</issue>): <fpage>2664</fpage>–<lpage>2676</lpage>.</citation>
</ref>
<ref id="bibr43-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>J.J.</given-names></name>
<name><surname>Galitzky</surname><given-names>M.</given-names></name>
<name><surname>Montastruc</surname><given-names>J.L.</given-names></name>
<name><surname>Rascol</surname><given-names>O.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Sleep attacks and Parkinson’s disease treatment</article-title>. <source>Lancet</source> <volume>355</volume>: <fpage>1333</fpage>–<lpage>1334</lpage>.</citation>
</ref>
<ref id="bibr44-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Finazzi-Agrò</surname><given-names>E.</given-names></name>
<name><surname>Peppe</surname><given-names>A.</given-names></name>
<name><surname>D’Amico</surname><given-names>A.</given-names></name>
<name><surname>Petta</surname><given-names>F.</given-names></name>
<name><surname>Mazzone</surname><given-names>P.</given-names></name>
<name><surname>Stanzione</surname><given-names>P.</given-names></name>
<etal/>
</person-group> (<year>2003</year>) <article-title>Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson’s disease</article-title>. <source>Urology</source> <volume>169</volume>: <fpage>1388</fpage>–<lpage>1391</lpage>.</citation>
</ref>
<ref id="bibr45-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Follett</surname><given-names>K.A.</given-names></name>
<name><surname>Weaver</surname><given-names>F.M.</given-names></name>
<name><surname>Stern</surname><given-names>M.</given-names></name>
<name><surname>Hur</surname><given-names>K.</given-names></name>
<name><surname>Harris</surname><given-names>C.L.</given-names></name>
<name><surname>Luo</surname><given-names>P.</given-names></name>
<etal/>
</person-group> <collab>CSP 468 Study Group</collab>. (<year>2010</year>) <article-title>Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease</article-title>. <source>N Engl J Med</source> <volume>362</volume>: <fpage>2077</fpage>–<lpage>2091</lpage>.</citation>
</ref>
<ref id="bibr46-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frankemolle</surname><given-names>A.M.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Noecker</surname><given-names>A.M.</given-names></name>
<name><surname>Voelcker-Rehage</surname><given-names>C.</given-names></name>
<name><surname>Ho</surname><given-names>J.C.</given-names></name>
<name><surname>Vitek</surname><given-names>J.L.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Reversing cognitive-motor impairments in Parkinson’s disease patients using a computational modelling approach to deep brain stimulation programming</article-title>. <source>Brain</source> <volume>33</volume>: <fpage>746</fpage>–<lpage>761</lpage>.</citation>
</ref>
<ref id="bibr47-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frucht</surname><given-names>S.</given-names></name>
<name><surname>Rogers</surname><given-names>J.D.</given-names></name>
<name><surname>Greene</surname><given-names>P.E.</given-names></name>
<name><surname>Gordon</surname><given-names>M.F.</given-names></name>
<name><surname>Fahn</surname><given-names>S.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole</article-title>. <source>Neurology</source> <volume>52</volume>: <fpage>1908</fpage>–<lpage>1910</lpage>.</citation>
</ref>
<ref id="bibr48-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Funkiewiez</surname><given-names>A.</given-names></name>
<name><surname>Ardouin</surname><given-names>C.</given-names></name>
<name><surname>Caputo</surname><given-names>E.</given-names></name>
<name><surname>Krack</surname><given-names>P.</given-names></name>
<name><surname>Fraix</surname><given-names>V.</given-names></name>
<name><surname>Klinger</surname><given-names>H.</given-names></name>
<etal/>
</person-group> (<year>2004</year>) <article-title>Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behavior in Parkinson’s disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>75</volume>: <fpage>834</fpage>–<lpage>839</lpage>.</citation>
</ref>
<ref id="bibr49-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerdelat-Mas</surname><given-names>A.</given-names></name>
<name><surname>Simonetta-Moreau</surname><given-names>M.</given-names></name>
<name><surname>Thalamas</surname><given-names>C.</given-names></name>
<name><surname>Ory-Magne</surname><given-names>F.</given-names></name>
<name><surname>Slaoui</surname><given-names>T.</given-names></name>
<name><surname>Rascol</surname><given-names>O.</given-names></name>
<etal/>
</person-group> (<year>2007</year>) <article-title>Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>78</volume>: <fpage>1140</fpage>–<lpage>1142</lpage>.</citation>
</ref>
<ref id="bibr50-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gierthmühlen</surname><given-names>J.</given-names></name>
<name><surname>Arning</surname><given-names>P.</given-names></name>
<name><surname>Binder</surname><given-names>A.</given-names></name>
<name><surname>Herzog</surname><given-names>J.</given-names></name>
<name><surname>Deuschl</surname><given-names>G.</given-names></name>
<name><surname>Wasner</surname><given-names>G.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Influence of deep brain stimulation and levodopa on sensory signs in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>25</volume>: <fpage>1195</fpage>–<lpage>1202</lpage>.</citation>
</ref>
<ref id="bibr51-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gironell</surname><given-names>A.</given-names></name>
<name><surname>Kulisevsky</surname><given-names>J.</given-names></name>
<name><surname>Rami</surname><given-names>L.</given-names></name>
<name><surname>Fortuny</surname><given-names>N.</given-names></name>
<name><surname>García-Sánchez</surname><given-names>C.</given-names></name>
<name><surname>Pascual-Sedano</surname><given-names>B.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Effects of pallidotomy and bilateral subthalamic stimulation on cognitive function in Parkinson disease. A controlled comparative study</article-title>. <source>J Neurol</source> <volume>250</volume>: <fpage>917</fpage>–<lpage>923</lpage>.</citation>
</ref>
<ref id="bibr52-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goetz</surname><given-names>C.G.</given-names></name>
<name><surname>Poewe</surname><given-names>W.</given-names></name>
<name><surname>Rascol</surname><given-names>O.</given-names></name>
<name><surname>Sampaio</surname><given-names>C.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004</article-title>. <source>Mov Disord</source> <volume>20</volume>: <fpage>523</fpage>–<lpage>539</lpage>.</citation>
</ref>
<ref id="bibr53-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldstein</surname><given-names>D.S.</given-names></name>
<name><surname>Holmes</surname><given-names>C.S.</given-names></name>
<name><surname>Dendi</surname><given-names>R.</given-names></name>
<name><surname>Bruce</surname><given-names>S.R.</given-names></name>
<name><surname>Li</surname><given-names>S.T.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Orthostatic hypotension from sympathetic denervation in Parkinson’s disease</article-title>. <source>Neurology</source> <volume>58</volume>: <fpage>1247</fpage>–<lpage>1255</lpage>.</citation>
</ref>
<ref id="bibr54-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guo</surname><given-names>X.</given-names></name>
<name><surname>Gao</surname><given-names>G.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Liang</surname><given-names>Q.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Effects of bilateral deep brain stimulation of the subthalamic nucleus on olfactory function in Parkinson’s disease patients</article-title>. <source>Stereotact Funct Neurosurg</source> <volume>86</volume>: <fpage>237</fpage>–<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr55-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Halpern</surname><given-names>C.H.</given-names></name>
<name><surname>Rick</surname><given-names>J.H.</given-names></name>
<name><surname>Danish</surname><given-names>S.F.</given-names></name>
<name><surname>Grossman</surname><given-names>M.</given-names></name>
<name><surname>Baltuch</surname><given-names>G.H.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Cognition following bilateral deep brain stimulation surgery of the subthalamic nucleus for Parkinson’s disease</article-title>. <source>Int J Geriatr Psychiatry</source> <volume>24</volume>: <fpage>443</fpage>–<lpage>451</lpage>.</citation>
</ref>
<ref id="bibr56-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hershey</surname><given-names>T.</given-names></name>
<name><surname>Revilla</surname><given-names>F.J.</given-names></name>
<name><surname>Wernle</surname><given-names>A.</given-names></name>
<name><surname>Gibson</surname><given-names>P.S.</given-names></name>
<name><surname>Dowling</surname><given-names>J.L.</given-names></name>
<name><surname>Perlmutter</surname><given-names>J.S.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Stimulation of STN impairs aspects of cognitive control in PD</article-title>. <source>Neurology</source> <volume>62</volume>: <fpage>1110</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr57-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herzog</surname><given-names>J.</given-names></name>
<name><surname>Weiss</surname><given-names>P.H.</given-names></name>
<name><surname>Assmus</surname><given-names>A.</given-names></name>
<name><surname>Wefer</surname><given-names>B.</given-names></name>
<name><surname>Seif</surname><given-names>C.</given-names></name>
<name><surname>Braun</surname><given-names>P.M.</given-names></name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson’s disease</article-title>. <source>Brain</source> <volume>129</volume>: <fpage>3366</fpage>–<lpage>3375</lpage>.</citation>
</ref>
<ref id="bibr58-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herzog</surname><given-names>J.</given-names></name>
<name><surname>Weiss</surname><given-names>P.H.</given-names></name>
<name><surname>Assmus</surname><given-names>A.</given-names></name>
<name><surname>Wefer</surname><given-names>B.</given-names></name>
<name><surname>Seif</surname><given-names>C.</given-names></name>
<name><surname>Braun</surname><given-names>P.M.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Improved sensory gating of urinary bladder afferents in Parkinson’s disease following subthalamic stimulation</article-title>. <source>Brain</source> <volume>131</volume>: <fpage>132</fpage>–<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr59-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hjort</surname><given-names>N.</given-names></name>
<name><surname>Østergaard</surname><given-names>K.</given-names></name>
<name><surname>Dupont</surname><given-names>E.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Improvement of sleep quality in patients with advanced Parkinson’s disease treated with deep brain stimulation of the subthalamic nucleus</article-title>. <source>Mov Disord</source> <volume>19</volume>: <fpage>196</fpage>–<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr60-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holmberg</surname><given-names>B.</given-names></name>
<name><surname>Corneliusson</surname><given-names>O.</given-names></name>
<name><surname>Elam</surname><given-names>M.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Bilateral stimulation of nucleus subthalamicus in advanced Parkinson’s disease: no effects on, and of, autonomic dysfunction</article-title>. <source>Mov Disord</source> <volume>20</volume>: <fpage>976</fpage>–<lpage>981</lpage>.</citation>
</ref>
<ref id="bibr61-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jahanshahi</surname><given-names>M.</given-names></name>
<name><surname>Wilkinson</surname><given-names>L.</given-names></name>
<name><surname>Gahir</surname><given-names>H.</given-names></name>
<name><surname>Dharminda</surname><given-names>A.</given-names></name>
<name><surname>Lagnado</surname><given-names>D.A.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Medication impairs probabilistic classification learning in Parkinson’s disease</article-title>. <source>Neuropsychologia</source> <volume>48</volume>: <fpage>1096</fpage>–<lpage>1103</lpage>.</citation>
</ref>
<ref id="bibr62-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jost</surname><given-names>W.H.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Autonomic dysfunctions in idiopathic Parkinson’s disease</article-title>. <source>J Neurol</source> <volume>250</volume>(<supplement>Suppl. 1</supplement>): <fpage>I28</fpage>–<lpage>I30</lpage>.</citation>
</ref>
<ref id="bibr63-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaufmann</surname><given-names>H.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>K.F.</given-names></name>
<name><surname>Voustianiouk</surname><given-names>A.</given-names></name>
<name><surname>Gracies</surname><given-names>J.M.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Stimulation of the subthalamic nucleus increases heart rate in patients with Parkinson’s disease</article-title>. <source>Neurology</source> <volume>59</volume>: <fpage>1657</fpage>–<lpage>1658</lpage>.</citation>
</ref>
<ref id="bibr64-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Paek</surname><given-names>S.H.</given-names></name>
<name><surname>Kim</surname><given-names>J.Y.</given-names></name>
<name><surname>Lee</surname><given-names>J.Y.</given-names></name>
<name><surname>Lim</surname><given-names>Y.H.</given-names></name>
<name><surname>Kim</surname><given-names>M.R.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Chronic subthalamic deep brain stimulation improves pain in Parkinson disease</article-title>. <source>J Neurol</source> <volume>255</volume>: <fpage>1889</fpage>–<lpage>1894</lpage>.</citation>
</ref>
<ref id="bibr65-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Park</surname><given-names>S.Y.</given-names></name>
<name><surname>Cho</surname><given-names>Y.J.</given-names></name>
<name><surname>Hong</surname><given-names>K.S.</given-names></name>
<name><surname>Cho</surname><given-names>J.Y.</given-names></name>
<name><surname>Seo</surname><given-names>S.Y.</given-names></name>
<etal/>
</person-group> (<year>2009</year>) <article-title>Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment</article-title>. <source>J Neurol Sci</source> <volume>287</volume>: <fpage>200</fpage>–<lpage>204</lpage>.</citation>
</ref>
<ref id="bibr66-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kirsch-Darrow</surname><given-names>L.</given-names></name>
<name><surname>Zahodne</surname><given-names>L.B.</given-names></name>
<name><surname>Marsiske</surname><given-names>M.</given-names></name>
<name><surname>Okun</surname><given-names>M.S.</given-names></name>
<name><surname>Foote</surname><given-names>K.D.</given-names></name>
<name><surname>Bowers</surname><given-names>D.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The trajectory of apathy after deep brain stimulation: from pre-surgery to 6 months post-surgery in Parkinson’s disease</article-title>. <source>Parkinsonism Relat Disord</source> <volume>17</volume>: <fpage>182</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr67-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klos</surname><given-names>K.J.</given-names></name>
<name><surname>Bower</surname><given-names>J.H.</given-names></name>
<name><surname>Josephs</surname><given-names>K.A.</given-names></name>
<name><surname>Matsumoto</surname><given-names>J.Y.</given-names></name>
<name><surname>Ahlskog</surname><given-names>J.E.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy</article-title>. <source>Parkinsonism Related Disord</source> <volume>11</volume>: <fpage>381</fpage>–<lpage>396</lpage>.</citation>
</ref>
<ref id="bibr68-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kujawa</surname><given-names>K.</given-names></name>
<name><surname>Leurgans</surname><given-names>S.</given-names></name>
<name><surname>Raman</surname><given-names>R.</given-names></name>
<name><surname>Blasucci</surname><given-names>L.</given-names></name>
<name><surname>Goetz</surname><given-names>C.G.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Acute orthostatic hypotension when starting dopamine agonists in Parkinson’s disease</article-title>. <source>Arch Neurol</source> <volume>57</volume>: <fpage>1461</fpage>–<lpage>1463</lpage>.</citation>
</ref>
<ref id="bibr69-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lawrence</surname><given-names>A.J.</given-names></name>
<name><surname>Blackwell</surname><given-names>A.D.</given-names></name>
<name><surname>Barker</surname><given-names>R.A.</given-names></name>
<name><surname>Spagnolo</surname><given-names>F.</given-names></name>
<name><surname>Clark</surname><given-names>L.</given-names></name>
<name><surname>Aitken</surname><given-names>M.R.</given-names></name>
<etal/>
</person-group> (<year>2007</year>) <article-title>Predictors of punding in Parkinson’s disease: results from a questionnaire survey</article-title>. <source>Mov Disord</source> <volume>22</volume>: <fpage>2339</fpage>–<lpage>2345</lpage>.</citation>
</ref>
<ref id="bibr70-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leentjens</surname><given-names>A.F.</given-names></name>
<name><surname>Koester</surname><given-names>J.</given-names></name>
<name><surname>Fruh</surname><given-names>B.</given-names></name>
<name><surname>Shephard</surname><given-names>D.T.</given-names></name>
<name><surname>Barone</surname><given-names>P.</given-names></name>
<name><surname>Houben</surname><given-names>J.J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>The effect of pramipexole on mood and motivational symptoms in Parkinson’s disease: a meta-analysis of placebo-controlled studies</article-title>. <source>Clin Ther</source> <volume>31</volume>: <fpage>89</fpage>–<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr71-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lim</surname><given-names>S.Y.</given-names></name>
<name><surname>Lang</surname><given-names>A.E.</given-names></name>
</person-group> (<year>2010</year>) <article-title>The nonmotor symptoms of Parkinson’s disease – an overview</article-title>. <source>Mov Disord</source> <volume>25</volume>(<supplement>Suppl.1</supplement>): <fpage>S123</fpage>–<lpage>S130</lpage>.</citation>
</ref>
<ref id="bibr72-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lipp</surname><given-names>A.</given-names></name>
<name><surname>Tank</surname><given-names>J.</given-names></name>
<name><surname>Trottenberg</surname><given-names>T.</given-names></name>
<name><surname>Kupsch</surname><given-names>A.</given-names></name>
<name><surname>Arnold</surname><given-names>G.</given-names></name>
<name><surname>Jordan</surname><given-names>J.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Sympathetic activation due to deep brain stimulation in the region of the STN</article-title>. <source>Neurology</source> <volume>65</volume>: <fpage>774</fpage>–<lpage>775</lpage>.</citation>
</ref>
<ref id="bibr73-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ludwig</surname><given-names>J.</given-names></name>
<name><surname>Remien</surname><given-names>P.</given-names></name>
<name><surname>Guballa</surname><given-names>C.</given-names></name>
<name><surname>Binder</surname><given-names>A.</given-names></name>
<name><surname>Binder</surname><given-names>S.</given-names></name>
<name><surname>Schattschneider</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2007</year>) <article-title>Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson’s disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>78</volume>: <fpage>742</fpage>–<lpage>745</lpage>.</citation>
</ref>
<ref id="bibr74-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lulé</surname><given-names>D.</given-names></name>
<name><surname>Heimrath</surname><given-names>J.</given-names></name>
<name><surname>Pinkhardt</surname><given-names>E.H.</given-names></name>
<name><surname>Ludolph</surname><given-names>A.C.</given-names></name>
<name><surname>Uttner</surname><given-names>I.</given-names></name>
<name><surname>Kassubek</surname><given-names>J.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Deep brain stimulation and behavioural changes: is comedication the most important factor?</article-title>. <source>Neurodegener Dis</source> <comment>2011 21 July [Epub ahead of print]</comment>.</citation>
</ref>
<ref id="bibr75-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lyons</surname><given-names>K.E.</given-names></name>
<name><surname>Pahwa</surname><given-names>R.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease</article-title>. <source>J Neurosurg</source> <volume>104</volume>: <fpage>502</fpage>–<lpage>505</lpage>.</citation>
</ref>
<ref id="bibr76-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lyytinen</surname><given-names>J.</given-names></name>
<name><surname>Sovijärvi</surname><given-names>A.</given-names></name>
<name><surname>Kaakkola</surname><given-names>S.</given-names></name>
<name><surname>Gordin</surname><given-names>A.</given-names></name>
<name><surname>Teräväinen</surname><given-names>H.</given-names></name>
</person-group> (<year>2001</year>) <article-title>The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson’s disease</article-title>. <source>Clin Neuropharmacol</source> <volume>24</volume>: <fpage>50</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr77-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maruo</surname><given-names>T.</given-names></name>
<name><surname>Saitoh</surname><given-names>Y.</given-names></name>
<name><surname>Hosomi</surname><given-names>K.</given-names></name>
<name><surname>Kishima</surname><given-names>H.</given-names></name>
<name><surname>Shimokawa</surname><given-names>T.</given-names></name>
<name><surname>Hirata</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2011</year>) <article-title>Deep brain stimulation of the subthalamic nucleus improves temperature sensation in patients with Parkinson’s disease</article-title>. <source>Pain</source> <volume>152</volume>: <fpage>860</fpage>–<lpage>865</lpage>.</citation>
</ref>
<ref id="bibr78-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Micallef</surname><given-names>J.</given-names></name>
<name><surname>Rey</surname><given-names>M.</given-names></name>
<name><surname>Eusebio</surname><given-names>A.</given-names></name>
<name><surname>Audebert</surname><given-names>C.</given-names></name>
<name><surname>Rouby</surname><given-names>F.</given-names></name>
<name><surname>Jouve</surname><given-names>E.</given-names></name>
<etal/>
</person-group> (<year>2009</year>) <article-title>Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects</article-title>. <source>Br J Clin Pharmacol</source> <volume>67</volume>: <fpage>333</fpage>–<lpage>340</lpage>.</citation>
</ref>
<ref id="bibr79-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Minguez-Castellanos</surname><given-names>A.</given-names></name>
<name><surname>Chamorro</surname><given-names>C.E.</given-names></name>
<name><surname>Escamilla-Sevilla</surname><given-names>F.</given-names></name>
<name><surname>Ortega-Moreno</surname><given-names>A.</given-names></name>
<name><surname>Rebollo</surname><given-names>A.C.</given-names></name>
<name><surname>Gomez-Rio</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2007</year>) <article-title>Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders? A cohort study</article-title>. <source>Neurology</source> <volume>68</volume>: <fpage>2012</fpage>–<lpage>2018</lpage>.</citation>
</ref>
<ref id="bibr80-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morgan</surname><given-names>J.C.</given-names></name>
<name><surname>Sethi</surname><given-names>K.D.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Rotigotine for the treatment of Parkinson’s disease</article-title>. <source>Expert Rev Neurother</source> <volume>6</volume>: <fpage>1275</fpage>–<lpage>1282</lpage>.</citation>
</ref>
<ref id="bibr81-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moro</surname><given-names>E.</given-names></name>
<name><surname>Lozano</surname><given-names>A.M.</given-names></name>
<name><surname>Pollak</surname><given-names>P.</given-names></name>
<name><surname>Agid</surname><given-names>Y.</given-names></name>
<name><surname>Rehncrona</surname><given-names>S.</given-names></name>
<name><surname>Volkmann</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>25</volume>: <fpage>578</fpage>–<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr82-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morrison</surname><given-names>C.E.</given-names></name>
<name><surname>Borod</surname><given-names>J.C.</given-names></name>
<name><surname>Perrine</surname><given-names>K.</given-names></name>
<name><surname>Beric</surname><given-names>A.</given-names></name>
<name><surname>Brin</surname><given-names>M.F.</given-names></name>
<name><surname>Rezai</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2004</year>) <article-title>Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson’s disease</article-title>. <source>Arch Clin Neuropsychol</source> <volume>19</volume>: <fpage>165</fpage>–<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr83-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nazem</surname><given-names>S.</given-names></name>
<name><surname>Siderowf</surname><given-names>A.D.</given-names></name>
<name><surname>Duda</surname><given-names>J.E.</given-names></name>
<name><surname>Brown</surname><given-names>G.K.</given-names></name>
<name><surname>Ten Have</surname><given-names>T.</given-names></name>
<name><surname>Stern</surname><given-names>M.B.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Suicidal and death ideation in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>23</volume>: <fpage>1573</fpage>–<lpage>1579</lpage>.</citation>
</ref>
<ref id="bibr84-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nazzaro</surname><given-names>J.M.</given-names></name>
<name><surname>Pahwa</surname><given-names>R.</given-names></name>
<name><surname>Lyons</surname><given-names>K.E.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The impact of bilateral subthalamic stimulation on on-motor symptoms of Parkinson’s disease</article-title>. <source>Parkinsonism Relat Disord</source> <comment>2011 11 June [Epub ahead of print]</comment>.</citation>
</ref>
<ref id="bibr85-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nebe</surname><given-names>A.</given-names></name>
<name><surname>Ebersbach</surname><given-names>G.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Pain intensity on and off levodopa in patients with Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>24</volume>: <fpage>1233</fpage>–<lpage>1237</lpage>.</citation>
</ref>
<ref id="bibr86-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oertel</surname><given-names>W.H.</given-names></name>
<name><surname>Wolters</surname><given-names>E.</given-names></name>
<name><surname>Sampaio</surname><given-names>C.</given-names></name>
<name><surname>Gimenez-Roldan</surname><given-names>S.</given-names></name>
<name><surname>Bergamasco</surname><given-names>B.</given-names></name>
<name><surname>Dujardin</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study</article-title>. <source>Mov Disord</source> <volume>21</volume>: <fpage>343</fpage>–<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr87-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Okun</surname><given-names>M.S.</given-names></name>
<name><surname>Fernandez</surname><given-names>H.H.</given-names></name>
<name><surname>Wu</surname><given-names>S.S.</given-names></name>
<name><surname>Kirsch-Darrow</surname><given-names>L.</given-names></name>
<name><surname>Bowers</surname><given-names>D.</given-names></name>
<name><surname>Bova</surname><given-names>F.</given-names></name>
<etal/>
</person-group> (<year>2009</year>) <article-title>Cognition and mood in Parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial</article-title>. <source>Ann Neurol</source> <volume>65</volume>: <fpage>586</fpage>–<lpage>595</lpage>.</citation>
</ref>
<ref id="bibr88-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olanow</surname><given-names>C.W.</given-names></name>
<name><surname>Stern</surname><given-names>M.B.</given-names></name>
<name><surname>Sethi</surname><given-names>K.</given-names></name>
</person-group> (<year>2009</year>) <article-title>The scientific and clinical basis for the treatment of Parkinson’s disease</article-title>. <source>Neurology</source> <volume>72</volume>(<supplement>Suppl. 4</supplement>): <fpage>S1</fpage>–<lpage>S136</lpage>.</citation>
</ref>
<ref id="bibr89-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orimo</surname><given-names>S.</given-names></name>
<name><surname>Oka</surname><given-names>T.</given-names></name>
<name><surname>Miura</surname><given-names>H.</given-names></name>
<etal/>
</person-group> (<year>2002</year>) <article-title>Sympathetic cardiac denervation in Parkinson’s disease and pure autonomic failure but not in multiple system atrophy</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>73</volume>: <fpage>776</fpage>–<lpage>777</lpage>.</citation>
</ref>
<ref id="bibr90-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oyama</surname><given-names>G.</given-names></name>
<name><surname>Shimo</surname><given-names>Y.</given-names></name>
<name><surname>Natori</surname><given-names>S.</given-names></name>
<name><surname>Nakajima</surname><given-names>M.</given-names></name>
<name><surname>Ishii</surname><given-names>H.</given-names></name>
<name><surname>Arai</surname><given-names>H.</given-names></name>
<etal/>
</person-group> (<year>2011</year>) <article-title>Acute effects of bilateral subthalamic stimulation on decision-making in Parkinson’s disease</article-title>. <source>Parkinsonism Relat Disord</source> <volume>17</volume>: <fpage>189</fpage>–<lpage>193</lpage>.</citation>
</ref>
<ref id="bibr91-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pahwa</surname><given-names>R.</given-names></name>
<name><surname>Factor</surname><given-names>S.A.</given-names></name>
<name><surname>Lyons</surname><given-names>K.E.</given-names></name>
<name><surname>Ondo</surname><given-names>W.G.</given-names></name>
<name><surname>Gronseth</surname><given-names>G.</given-names></name>
<name><surname>Bronte-Stewart</surname><given-names>H.</given-names></name>
<etal/>
</person-group> <collab>Quality Standards Subcommittee of the American Academy of Neurology</collab>. (<year>2006</year>) <article-title>Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology</article-title>. <source>Neurology</source> <volume>66</volume>: <fpage>983</fpage>–<lpage>995</lpage>.</citation>
</ref>
<ref id="bibr92-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pahwa</surname><given-names>R.</given-names></name>
<name><surname>Stacy</surname><given-names>M.A.</given-names></name>
<name><surname>Factor</surname><given-names>S.A.</given-names></name>
<name><surname>Lyons</surname><given-names>K.E.</given-names></name>
<name><surname>Stocchi</surname><given-names>F.</given-names></name>
<name><surname>Hersh</surname><given-names>B.P.</given-names></name>
<etal/>
</person-group> <collab>EASE-PD Adjunct Study Investigators</collab>. (<year>2007</year>) <article-title>Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease</article-title>. <source>Neurology</source> <volume>68</volume>: <fpage>1108</fpage>–<lpage>1115</lpage>.</citation>
</ref>
<ref id="bibr93-1756285611423412">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Parkinson</surname><given-names>J.</given-names></name>
</person-group> (<year>1817</year>) <source>An Essay on Shaking Palsy</source>, <publisher-name>Sherwood, Neely and Jones</publisher-name>: <publisher-loc>London</publisher-loc>.</citation>
</ref>
<ref id="bibr94-1756285611423412">
<citation citation-type="journal">
<collab>Parkinson Study Group</collab>. (<year>2000</year>) <article-title>Pramipexole vs levodopa as initial treatment for Parkinson’s disease</article-title>. <source>JAMA</source> <volume>284</volume>: <fpage>1931</fpage>–<lpage>1938</lpage>.</citation>
</ref>
<ref id="bibr95-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parsons</surname><given-names>T.D.</given-names></name>
<name><surname>Rogers</surname><given-names>S.A.</given-names></name>
<name><surname>Braaten</surname><given-names>A.J.</given-names></name>
<name><surname>Woods</surname><given-names>S.P.</given-names></name>
<name><surname>Tröster</surname><given-names>A.I.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson’s disease: a meta-analysis</article-title>. <source>Lancet Neurol</source> <volume>5</volume>: <fpage>578</fpage>–<lpage>588</lpage>.</citation>
</ref>
<ref id="bibr96-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pfeiffer</surname><given-names>R.F.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Gastrointestinal, urological, and sexual dysfunction in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>25</volume>(<supplement>Suppl. 1</supplement>): <fpage>S94</fpage>–<lpage>S97</lpage>.</citation>
</ref>
<ref id="bibr97-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poewe</surname><given-names>W.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Psychosis in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>18</volume>(<supplement>Suppl. 6</supplement>): <fpage>S80</fpage>–<lpage>S87</lpage>.</citation>
</ref>
<ref id="bibr98-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Porat</surname><given-names>O.</given-names></name>
<name><surname>Cohen</surname><given-names>O.S.</given-names></name>
<name><surname>Schwartz</surname><given-names>R.</given-names></name>
<name><surname>Hassin-Baer</surname><given-names>S.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Association of preoperative symptom profile with psychiatric symptoms following subthalamic nucleus stimulation in patients with Parkinson’s disease</article-title>. <source>J Neuropsychiatry Clin Neurosci</source> <volume>21</volume>: <fpage>398</fpage>–<lpage>405</lpage>.</citation>
</ref>
<ref id="bibr99-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Priori</surname><given-names>A.</given-names></name>
<name><surname>Cinnante</surname><given-names>C.</given-names></name>
<name><surname>Genitrini</surname><given-names>S.</given-names></name>
<name><surname>Pesenti</surname><given-names>A.</given-names></name>
<name><surname>Tortora</surname><given-names>G.</given-names></name>
<name><surname>Bencini</surname><given-names>C.</given-names></name>
<etal/>
</person-group> (<year>2001</year>) <article-title>Non-motor effects of deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: preliminary physiological results</article-title>. <source>Neurol Sci</source> <volume>22</volume>: <fpage>85</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr100-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pursiainen</surname><given-names>V.</given-names></name>
<name><surname>Haapaniemi</surname><given-names>T.H.</given-names></name>
<name><surname>Korpelainen</surname><given-names>J.T.</given-names></name>
<name><surname>Sotaniemi</surname><given-names>K.A.</given-names></name>
<name><surname>Myllyla</surname><given-names>V.V.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Sweating in Parkinsonian patients with wearing-off</article-title>. <source>Mov Disord</source> <volume>22</volume>: <fpage>828</fpage>–<lpage>832</lpage>.</citation>
</ref>
<ref id="bibr101-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rascol</surname><given-names>O.</given-names></name>
<name><surname>Brooks</surname><given-names>D.J.</given-names></name>
<name><surname>Korczyn</surname><given-names>A.D.</given-names></name>
<name><surname>De Deyn</surname><given-names>P.P.</given-names></name>
<name><surname>Clarke</surname><given-names>C.E.</given-names></name>
<name><surname>Lang</surname><given-names>A.E.</given-names></name>
</person-group> (<year>2000</year>) <article-title>A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levdodopa</article-title>. <source>N Engl J Med</source> <volume>342</volume>: <fpage>1484</fpage>–<lpage>1491</lpage>.</citation>
</ref>
<ref id="bibr102-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rektorová</surname><given-names>I.</given-names></name>
<name><surname>Rektor</surname><given-names>I.</given-names></name>
<name><surname>Bares</surname><given-names>M.</given-names></name>
<name><surname>Dostál</surname><given-names>V.</given-names></name>
<name><surname>Ehler</surname><given-names>E.</given-names></name>
<name><surname>Fanfrdlová</surname><given-names>Z.</given-names></name>
<etal/>
</person-group> (<year>2003</year>) <article-title>Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study</article-title>. <source>Eur J Neurol</source> <volume>10</volume>: <fpage>399</fpage>–<lpage>406</lpage>.</citation>
</ref>
<ref id="bibr103-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rektorová</surname><given-names>I.</given-names></name>
<name><surname>Rektor</surname><given-names>I.</given-names></name>
<name><surname>Bares</surname><given-names>M.</given-names></name>
<name><surname>Dostál</surname><given-names>V.</given-names></name>
<name><surname>Ehler</surname><given-names>E.</given-names></name>
<name><surname>Fanfrdlová</surname><given-names>Z.</given-names></name>
<etal/>
</person-group> (<year>2005</year>) <article-title>Cognitive performance in people with Parkinson’s disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy</article-title>. <source>Eur J Neurol</source> <volume>12</volume>: <fpage>9</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr104-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rektorová</surname><given-names>I.</given-names></name>
<name><surname>Balaz</surname><given-names>M.</given-names></name>
<name><surname>Svatova</surname><given-names>J.</given-names></name>
<name><surname>Zarubova</surname><given-names>K.</given-names></name>
<name><surname>Honig</surname><given-names>I.</given-names></name>
<name><surname>Dostal</surname><given-names>V.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study</article-title>. <source>Clin Neuropharmacol</source> <volume>31</volume>: <fpage>261</fpage>–<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr105-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reuter</surname><given-names>I.</given-names></name>
<name><surname>Ellis</surname><given-names>C.M.</given-names></name>
<name><surname>Ray Chaudhuri</surname><given-names>K.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Nocturnal subcutaneous apomorphine infusion in Parkinson’s disease and restless legs syndrome</article-title>. <source>Acta Neurol Scand</source> <volume>100</volume>: <fpage>163</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr106-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rinne</surname><given-names>U.K.</given-names></name>
<name><surname>Bracco</surname><given-names>F.</given-names></name>
<name><surname>Chouza</surname><given-names>C.</given-names></name>
<name><surname>Dupont</surname><given-names>E.</given-names></name>
<name><surname>Gershanik</surname><given-names>O.</given-names></name>
<name><surname>Marti Masso</surname><given-names>J.F.</given-names></name>
<etal/>
</person-group> <collab>PKDS009 Study Group</collab>. (<year>1998</year>) <article-title>Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications</article-title>. <source>Drugs</source> <volume>55</volume>(<supplement>Suppl. 1</supplement>): <fpage>23</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr107-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roane</surname><given-names>D.M.</given-names></name>
<name><surname>Yu</surname><given-names>M.</given-names></name>
<name><surname>Feinberg</surname><given-names>T.E.</given-names></name>
<name><surname>Rogers</surname><given-names>J.D.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Hypersexuality after pallidal surgery in Parkinson’s disease</article-title>. <source>Neuropsychiatry Neuropsychol Behave Neurol</source> <volume>15</volume>: <fpage>247</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr108-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Romito</surname><given-names>L.M.</given-names></name>
<name><surname>Raja</surname><given-names>M.</given-names></name>
<name><surname>Daniele</surname><given-names>A.</given-names></name>
<name><surname>Contarino</surname><given-names>M.F.</given-names></name>
<name><surname>Bentivoglio</surname><given-names>A.R.</given-names></name>
<name><surname>Barbier</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2002</year>) <article-title>Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>17</volume>: <fpage>1371</fpage>–<lpage>1374</lpage>.</citation>
</ref>
<ref id="bibr109-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rothlind</surname><given-names>J.C.</given-names></name>
<name><surname>Cockshott</surname><given-names>R.W.</given-names></name>
<name><surname>Starr</surname><given-names>P.A.</given-names></name>
<name><surname>Marks</surname><given-names>W.J.</given-names><suffix>Jr</suffix></name>
</person-group> (<year>2007</year>) <article-title>Neuropsychological performance following staged bilateral pallidal or subthalamic nucleus deep brain stimulation for Parkinson’s disease</article-title>. <source>J Int Neuropsychol Soc</source> <volume>13</volume>: <fpage>68</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr110-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sakakibara</surname><given-names>R.</given-names></name>
<name><surname>Uchiyama</surname><given-names>T.</given-names></name>
<name><surname>Yamanishi</surname><given-names>T.</given-names></name>
<name><surname>Kishi</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Genitourinary dysfunction in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>25</volume>: <fpage>2</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr111-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schapira</surname><given-names>A.H.V.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Sleep attacks (sleep episodes) with pergolide</article-title>. <source>Lancet</source> <volume>355</volume>: <fpage>1332</fpage>–<lpage>1333</lpage>.</citation>
</ref>
<ref id="bibr112-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seif</surname><given-names>C.</given-names></name>
<name><surname>Herzog</surname><given-names>J.</given-names></name>
<name><surname>van der Horst</surname><given-names>C.</given-names></name>
<name><surname>Schrader</surname><given-names>B.</given-names></name>
<name><surname>Volkmann</surname><given-names>J.</given-names></name>
<name><surname>Deuschl</surname><given-names>G.</given-names></name>
<etal/>
</person-group> (<year>2004</year>) <article-title>Effect of subthalamic deep brain stimulation on the function of the urinary bladder</article-title>. <source>Ann Neurol</source> <volume>55</volume>: <fpage>118</fpage>–<lpage>120</lpage>.</citation>
</ref>
<ref id="bibr113-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimizu</surname><given-names>N.</given-names></name>
<name><surname>Matsumoto</surname><given-names>S.</given-names></name>
<name><surname>Mori</surname><given-names>Y.</given-names></name>
<name><surname>Yoshioka</surname><given-names>N.</given-names></name>
<name><surname>Uemura</surname><given-names>H.</given-names></name>
<name><surname>Nakano</surname><given-names>N.</given-names></name>
<etal/>
</person-group> (<year>2007</year>) <article-title>Effects of deep brain stimulation on urodynamic findings in patients with Parkinson’s disease</article-title>. <source>Hinyokika Kiyo</source> <volume>53</volume>: <fpage>609</fpage>–<lpage>612</lpage>.</citation>
</ref>
<ref id="bibr114-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Slaoui</surname><given-names>T.</given-names></name>
<name><surname>Mas-Gerdelat</surname><given-names>A.</given-names></name>
<name><surname>Ory-Magne</surname><given-names>F.</given-names></name>
<name><surname>Rascol</surname><given-names>O.</given-names></name>
<name><surname>Brefel-Courbon</surname><given-names>C.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Levodopa modifies pain thresholds in Parkinson’s disease patients</article-title>. <source>Rev Neurol</source> <volume>163</volume>: <fpage>66</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr115-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smeding</surname><given-names>H.M.</given-names></name>
<name><surname>Speelman</surname><given-names>J.D.</given-names></name>
<name><surname>Huizenga</surname><given-names>H.M.</given-names></name>
<name><surname>Schuurman</surname><given-names>P.R.</given-names></name>
<name><surname>Schmand</surname><given-names>B.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson’s Disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>82</volume>: <fpage>754</fpage>–<lpage>760</lpage>.</citation>
</ref>
<ref id="bibr116-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smeding</surname><given-names>H.M.</given-names></name>
<name><surname>Speelman</surname><given-names>J.D.</given-names></name>
<name><surname>Koning-Haanstra</surname><given-names>M.</given-names></name>
<name><surname>Schuurman</surname><given-names>P.R.</given-names></name>
<name><surname>Nijssen</surname><given-names>P.</given-names></name>
<name><surname>van Laar</surname><given-names>T.</given-names></name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study</article-title>. <source>Neurology</source> <volume>66</volume>: <fpage>1830</fpage>–<lpage>1836</lpage>.</citation>
</ref>
<ref id="bibr117-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soulas</surname><given-names>T.</given-names></name>
<name><surname>Gurruchaga</surname><given-names>J.M.</given-names></name>
<name><surname>Palfi</surname><given-names>S.</given-names></name>
<name><surname>Cesaro</surname><given-names>P.</given-names></name>
<name><surname>Nguyen</surname><given-names>J.P.</given-names></name>
<name><surname>Fenelon</surname><given-names>G.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson’s disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>79</volume>: <fpage>952</fpage>–<lpage>954</lpage>.</citation>
</ref>
<ref id="bibr118-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Speiser</surname><given-names>Z.</given-names></name>
<name><surname>Levy</surname><given-names>R.</given-names></name>
<name><surname>Cohen</surname><given-names>S.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders</article-title>. <source>J Neural Transm</source> <volume>52</volume>(<supplement>Suppl</supplement>): <fpage>287</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr119-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stemper</surname><given-names>B.</given-names></name>
<name><surname>Beric</surname><given-names>A.</given-names></name>
<name><surname>Welsch</surname><given-names>G.</given-names></name>
<name><surname>Haendl</surname><given-names>T.</given-names></name>
<name><surname>Sterio</surname><given-names>D.</given-names></name>
<name><surname>Hilz</surname><given-names>M.J.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Deep brain stimulation improves orthostatic regulation of patients with Parkinson disease</article-title>. <source>Neurology</source> <volume>67</volume>: <fpage>1781</fpage>–<lpage>1785</lpage>.</citation>
</ref>
<ref id="bibr120-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stiasny-Kolster</surname><given-names>K.</given-names></name>
<name><surname>Kohnen</surname><given-names>R.</given-names></name>
<name><surname>Schollmayer</surname><given-names>E.</given-names></name>
<name><surname>Moller</surname><given-names>J.C.</given-names></name>
<name><surname>Oertel</surname><given-names>W.H.</given-names></name>
</person-group> <collab>Rotigotine Sp 666 Study Group</collab>. (<year>2004</year>) <article-title>Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study</article-title>. <source>Mov Disord</source> <volume>19</volume>: <fpage>1432</fpage>–<lpage>1438</lpage>.</citation>
</ref>
<ref id="bibr121-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stowe</surname><given-names>R.</given-names></name>
<name><surname>Ives</surname><given-names>N.</given-names></name>
<name><surname>Clarke</surname><given-names>C.E.</given-names></name>
<name><surname>Handley</surname><given-names>K.</given-names></name>
<name><surname>Furmston</surname><given-names>A.</given-names></name>
<name><surname>Deane</surname><given-names>K.</given-names></name>
<etal/>
</person-group> (<year>2011</year>) <article-title>Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>26</volume>: <fpage>587</fpage>–<lpage>598</lpage>.</citation>
</ref>
<ref id="bibr122-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stowe</surname><given-names>R.L.</given-names></name>
<name><surname>Ives</surname><given-names>N.J.</given-names></name>
<name><surname>Clarke</surname><given-names>C.</given-names></name>
<name><surname>van Hilten</surname><given-names>J.</given-names></name>
<name><surname>Ferreira</surname><given-names>J.</given-names></name>
<name><surname>Hawker</surname><given-names>R.J.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Dopamine agonist therapy in early Parkinson’s disease</article-title>. <source>Cochrane Database Syst Rev</source> <volume>2008</volume>(<issue>2</issue>): <fpage>CD006564</fpage>.</citation>
</ref>
<ref id="bibr123-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Strutt</surname><given-names>A.M.</given-names></name>
<name><surname>Simpson</surname><given-names>R.</given-names></name>
<name><surname>Jankovic</surname><given-names>J.</given-names></name>
<name><surname>York</surname><given-names>M.K.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson’s disease</article-title>. <source>Eur J Neurol</source> <day>11</day> <month>Jun</month> doi: 10.1111/j.1468-1331.2011.03447.x<pub-id pub-id-type="doi">10.1111/j.1468-1331.2011.03447.x</pub-id> [<comment>Epub ahead of print</comment>].</citation>
</ref>
<ref id="bibr124-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Swinn</surname><given-names>L.</given-names></name>
<name><surname>Schrag</surname><given-names>A.</given-names></name>
<name><surname>Viswanathan</surname><given-names>R.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Sweating dysfunction in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>18</volume>: <fpage>1459</fpage>–<lpage>1463</lpage>.</citation>
</ref>
<ref id="bibr125-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takahata</surname><given-names>K.</given-names></name>
<name><surname>Minami</surname><given-names>A.</given-names></name>
<name><surname>Kusumoto</surname><given-names>H.</given-names></name>
<name><surname>Shimazu</surname><given-names>S.</given-names></name>
<name><surname>Yoneda</surname><given-names>F.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Effects of selegiline alone or with donepezil on memory impairment in rats</article-title>. <source>Eur J Pharmacol</source> <volume>518</volume>: <fpage>140</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr126-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takeshita</surname><given-names>S.</given-names></name>
<name><surname>Kurisu</surname><given-names>K.</given-names></name>
<name><surname>Trop</surname><given-names>L.</given-names></name>
<name><surname>Arita</surname><given-names>K.</given-names></name>
<name><surname>Akimitsu</surname><given-names>T.</given-names></name>
<name><surname>Verhoeff</surname><given-names>N.P.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Effect of subthalamic stimulation on mood state in Parkinson’s disease: evaluation of previous facts and problems</article-title>. <source>Neurosurg Rev</source> <volume>28</volume>: <fpage>179</fpage>–<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr127-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tateno</surname><given-names>F.</given-names></name>
<name><surname>Sakakibara</surname><given-names>R.</given-names></name>
<name><surname>Yokoi</surname><given-names>Y.</given-names></name>
<name><surname>Kishi</surname><given-names>M.</given-names></name>
<name><surname>Ogawa</surname><given-names>E.</given-names></name>
<name><surname>Uchiyama</surname><given-names>T.</given-names></name>
<etal/>
</person-group> (<year>2011</year>) <article-title>Levodopa ameliorated anorectal constipation in de novo Parkinson’s disease: the QL-GAT study</article-title>. <source>Parkinsonism Relat Disord</source> <comment>2011 24 June [Epub ahead of print]</comment>.</citation>
</ref>
<ref id="bibr128-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Temel</surname><given-names>Y.</given-names></name>
<name><surname>Kessels</surname><given-names>A.</given-names></name>
<name><surname>Tan</surname><given-names>S.</given-names></name>
<name><surname>Topdag</surname><given-names>A.</given-names></name>
<name><surname>Boon</surname><given-names>P.</given-names></name>
<name><surname>Visser-Vandewalle</surname><given-names>V.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review</article-title>. <source>Parkinsonism Relat Disord</source> <volume>12</volume>: <fpage>265</fpage>–<lpage>272</lpage>.</citation>
</ref>
<ref id="bibr129-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thobois</surname><given-names>S.</given-names></name>
<name><surname>Ardouin</surname><given-names>C.</given-names></name>
<name><surname>Lhommée</surname><given-names>E.</given-names></name>
<name><surname>Klinger</surname><given-names>H.</given-names></name>
<name><surname>Lagrange</surname><given-names>C.</given-names></name>
<name><surname>Xie</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation</article-title>. <source>Brain</source> <volume>133</volume>: <fpage>1111</fpage>–<lpage>1127</lpage>.</citation>
</ref>
<ref id="bibr130-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thornton</surname><given-names>J.M.</given-names></name>
<name><surname>Aziz</surname><given-names>T.</given-names></name>
<name><surname>Schlugman</surname><given-names>D.</given-names></name>
<name><surname>Paterson</surname><given-names>D.J.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Electrical stimulation of the midbrain increases heart rate and arterial blood pressure in awake humans</article-title>. <source>J Physiol</source> <volume>539</volume>: <fpage>615</fpage>–<lpage>621</lpage>.</citation>
</ref>
<ref id="bibr131-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trachani</surname><given-names>E.</given-names></name>
<name><surname>Constantoyannis</surname><given-names>C.</given-names></name>
<name><surname>Sirrou</surname><given-names>V.</given-names></name>
<name><surname>Kefalopoulou</surname><given-names>Z.</given-names></name>
<name><surname>Markaki</surname><given-names>E.</given-names></name>
<name><surname>Chroni</surname><given-names>E.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Effects of subthalamic nucleus deep brain stimulation on sweating function in Parkinson’s disease</article-title>. <source>Clin Neurol Neurosurg</source> <volume>112</volume>: <fpage>213</fpage>–<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr132-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trenkwalder</surname><given-names>C.</given-names></name>
<name><surname>Kies</surname><given-names>B.</given-names></name>
<name><surname>Rudzinska</surname><given-names>M.</given-names></name>
<name><surname>Fine</surname><given-names>J.</given-names></name>
<name><surname>Nikl</surname><given-names>J.</given-names></name>
<name><surname>Honczarenko</surname><given-names>K.</given-names></name>
<etal/>
</person-group> <collab>Recover Study Group</collab>. (<year>2011</year>) <article-title>Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER)</article-title>. <source>Mov Disord</source> <volume>26</volume>: <fpage>90</fpage>–<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr133-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vignatelli</surname><given-names>L.</given-names></name>
<name><surname>Billiard</surname><given-names>M.</given-names></name>
<name><surname>Clarenbach</surname><given-names>P.</given-names></name>
<name><surname>Garcia-Borreguero</surname><given-names>D.</given-names></name>
<name><surname>Kaynak</surname><given-names>D.</given-names></name>
<name><surname>Liesiene</surname><given-names>V.</given-names></name>
<etal/>
</person-group> <collab>EFNS Task Force</collab>. (<year>2006</year>) <article-title>EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep</article-title>. <source>Eur J Neurol</source> <volume>13</volume>: <fpage>1049</fpage>–<lpage>1065</lpage>.</citation>
</ref>
<ref id="bibr134-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Visser</surname><given-names>M.</given-names></name>
<name><surname>Marinus</surname><given-names>J.</given-names></name>
<name><surname>Stiggelbout</surname><given-names>A.M.</given-names></name>
<name><surname>Van Hilten</surname><given-names>J.J.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPAAUT</article-title>. <source>Mov Disord</source> <volume>19</volume>: <fpage>1306</fpage>–<lpage>1312</lpage>.</citation>
</ref>
<ref id="bibr135-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Volkmann</surname><given-names>J.</given-names></name>
<name><surname>Albanese</surname><given-names>A.</given-names></name>
<name><surname>Kulisevsky</surname><given-names>J.</given-names></name>
<name><surname>Tornqvist</surname><given-names>A.L.</given-names></name>
<name><surname>Houeto</surname><given-names>J.L.</given-names></name>
<name><surname>Pidoux</surname><given-names>B.</given-names></name>
<etal/>
</person-group> (<year>2009</year>) <article-title>Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>24</volume>: <fpage>1154</fpage>–<lpage>1161</lpage>.</citation>
</ref>
<ref id="bibr136-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Voon</surname><given-names>V.</given-names></name>
<name><surname>Kubu</surname><given-names>C.</given-names></name>
<name><surname>Krack</surname><given-names>P.</given-names></name>
<name><surname>Houeto</surname><given-names>J.L.</given-names></name>
<name><surname>Tröster</surname><given-names>A.I.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Deep brain stimulation: neuropsychological and neuropsychiatric issues</article-title>. <source>Mov Disord</source> <volume>21</volume>(<supplement>Suppl. 14</supplement>): <fpage>S305</fpage>–<lpage>S327</lpage>.</citation>
</ref>
<ref id="bibr137-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Voon</surname><given-names>V.</given-names></name>
<name><surname>Krack</surname><given-names>P.</given-names></name>
<name><surname>Lang</surname><given-names>A.E.</given-names></name>
<name><surname>Lozano</surname><given-names>A.M.</given-names></name>
<name><surname>Dujardin</surname><given-names>K.</given-names></name>
<name><surname>Schüpbach</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease</article-title>. <source>Brain</source> <volume>31</volume>: <fpage>2720</fpage>–<lpage>2728</lpage>.</citation>
</ref>
<ref id="bibr138-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walters</surname><given-names>A.S.</given-names></name>
<name><surname>Ondo</surname><given-names>W.G.</given-names></name>
<name><surname>Dreykluft</surname><given-names>T.</given-names></name>
<name><surname>Grunstein</surname><given-names>R.</given-names></name>
<name><surname>Lee</surname><given-names>D.</given-names></name>
<name><surname>Sethi</surname><given-names>K.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo controlled study</article-title>. <source>Mov Disord</source> <volume>19</volume>: <fpage>1414</fpage>–<lpage>1423</lpage>.</citation>
</ref>
<ref id="bibr139-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Chang</surname><given-names>C.</given-names></name>
<name><surname>Geng</surname><given-names>N.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2009</year>) <article-title>Long-term effects of bilateral deep brain stimulation of the subthalamic nucleus on depression in patients with Parkinson’s disease</article-title>. <source>Parkinsonism Relat Disord</source> <volume>15</volume>: <fpage>587</fpage>–<lpage>591</lpage>.</citation>
</ref>
<ref id="bibr140-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weaver</surname><given-names>F.M.</given-names></name>
<name><surname>Follett</surname><given-names>K.</given-names></name>
<name><surname>Stern</surname><given-names>M.</given-names></name>
<name><surname>Hur</surname><given-names>K.</given-names></name>
<name><surname>Harris</surname><given-names>C.</given-names></name>
<name><surname>Marks</surname><given-names>W.J.</given-names><suffix>Jr</suffix></name>
<etal/>
</person-group> <collab>CSP 468 Study Group</collab>. (<year>2009</year>) <article-title>Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial</article-title>. <source>JAMA</source> <volume>301</volume>: <fpage>63</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr141-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weintraub</surname><given-names>D.</given-names></name>
<name><surname>Siderowf</surname><given-names>A.D.</given-names></name>
<name><surname>Potenza</surname><given-names>M.N.</given-names></name>
<name><surname>Goveas</surname><given-names>J.</given-names></name>
<name><surname>Morales</surname><given-names>K.H.</given-names></name>
<name><surname>Duda</surname><given-names>J.E.</given-names></name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Association of dopamine agonist use with impulse control disorders in Parkinson disease</article-title>. <source>Arch Neurol</source> <volume>63</volume>(<issue>7</issue>): <fpage>969</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr142-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weintraub</surname><given-names>D.</given-names></name>
<name><surname>Koester</surname><given-names>J.</given-names></name>
<name><surname>Potenza</surname><given-names>M.N.</given-names></name>
<name><surname>Siderowf</surname><given-names>A.D.</given-names></name>
<name><surname>Stacy</surname><given-names>M.</given-names></name>
<name><surname>Voon</surname><given-names>V.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients</article-title>. <source>Arch Neurol</source> <volume>67</volume>: <fpage>589</fpage>–<lpage>595</lpage>.</citation>
</ref>
<ref id="bibr143-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Williams</surname><given-names>A.</given-names></name>
<name><surname>Gill</surname><given-names>S.</given-names></name>
<name><surname>Varma</surname><given-names>T.</given-names></name>
<name><surname>Jenkinson</surname><given-names>C.</given-names></name>
<name><surname>Quinn</surname><given-names>N.</given-names></name>
<name><surname>Mitchell</surname><given-names>R.</given-names></name>
<etal/>
</person-group> <collab>PD SURG Collaborative Group</collab>. (<year>2010</year>) <article-title>Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial</article-title>. <source>Lancet Neurol</source> <volume>9</volume>: <fpage>581</fpage>–<lpage>591</lpage>.</citation>
</ref>
<ref id="bibr144-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Williams</surname><given-names>A.E.</given-names></name>
<name><surname>Arzola</surname><given-names>G.M.</given-names></name>
<name><surname>Strutt</surname><given-names>A.M.</given-names></name>
<name><surname>Simpson</surname><given-names>R.</given-names></name>
<name><surname>Jankovic</surname><given-names>J.</given-names></name>
<name><surname>York</surname><given-names>M.K.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation</article-title>. <source>Parkinsonism Relat Disord</source> <volume>17</volume>: <fpage>321</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr145-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winge</surname><given-names>K.</given-names></name>
<name><surname>Fowler</surname><given-names>C.J.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management</article-title>. <source>Mov Disord</source> <volume>21</volume>: <fpage>737</fpage>–<lpage>745</lpage>.</citation>
</ref>
<ref id="bibr146-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winge</surname><given-names>K.</given-names></name>
<name><surname>Nielsen</surname><given-names>K.K.</given-names></name>
<name><surname>Stimpel</surname><given-names>H.</given-names></name>
<name><surname>Lokkegaard</surname><given-names>A.</given-names></name>
<name><surname>Jensen</surname><given-names>S.R.</given-names></name>
<name><surname>Werdelin</surname><given-names>L.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Lower urinary tract symptoms and bladder control in advanced Parkinson’s disease: effects of deep brain stimulation in the subthalamic nucleus</article-title>. <source>Mov Disord</source> <volume>22</volume>: <fpage>220</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr147-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winge</surname><given-names>K.</given-names></name>
<name><surname>Werdelin</surname><given-names>L.M.</given-names></name>
<name><surname>Nielsen</surname><given-names>K.K.</given-names></name>
<name><surname>Stimpel</surname><given-names>H.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Effects of dopaminergic treatment on bladder function in Parkinson’s disease</article-title>. <source>Neurourol Urodyn</source> <volume>23</volume>: <fpage>689</fpage>–<lpage>696</lpage>.</citation>
</ref>
<ref id="bibr148-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winkelman</surname><given-names>J.W.</given-names></name>
<name><surname>Sethi</surname><given-names>K.D.</given-names></name>
<name><surname>Kushida</surname><given-names>C.A.</given-names></name>
<name><surname>Becker</surname><given-names>P.M.</given-names></name>
<name><surname>Koester</surname><given-names>J.</given-names></name>
<name><surname>Cappola</surname><given-names>J.J.</given-names></name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Efficacy and safety of pramipexole in restless legs syndrome</article-title>. <source>Neurology</source> <volume>67</volume>: <fpage>1034</fpage>–<lpage>1039</lpage>.</citation>
</ref>
<ref id="bibr149-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Witjas</surname><given-names>T.</given-names></name>
<name><surname>Kaphan</surname><given-names>E.</given-names></name>
<name><surname>Régis</surname><given-names>J.</given-names></name>
<name><surname>Jouve</surname><given-names>E.</given-names></name>
<name><surname>Chérif</surname><given-names>A.A.</given-names></name>
<name><surname>Péragut</surname><given-names>J.C.</given-names></name>
<etal/>
</person-group> (<year>2007</year>) <article-title>Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>22</volume>: <fpage>1729</fpage>–<lpage>1734</lpage>.</citation>
</ref>
<ref id="bibr150-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Witt</surname><given-names>K.</given-names></name>
<name><surname>Daniels</surname><given-names>C.</given-names></name>
<name><surname>Reiff</surname><given-names>J.</given-names></name>
<name><surname>Krack</surname><given-names>P.</given-names></name>
<name><surname>Volkmann</surname><given-names>J.</given-names></name>
<name><surname>Pinsker</surname><given-names>M.O.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study</article-title>. <source>Lancet Neurol</source> <volume>7</volume>: <fpage>605</fpage>–<lpage>614</lpage>.</citation>
</ref>
<ref id="bibr151-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>York</surname><given-names>M.K.</given-names></name>
<name><surname>Dulay</surname><given-names>M.</given-names></name>
<name><surname>Macias</surname><given-names>A.</given-names></name>
<name><surname>Levin</surname><given-names>H.S.</given-names></name>
<name><surname>Grossman</surname><given-names>R.</given-names></name>
<name><surname>Simpson</surname><given-names>R.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson’s disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>79</volume>: <fpage>789</fpage>–<lpage>795</lpage>.</citation>
</ref>
<ref id="bibr152-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Youdim</surname><given-names>M.B.</given-names></name>
<name><surname>Bakhle</surname><given-names>Y.S.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness</article-title>. <source>Br J Pharmacol</source> <volume>147</volume>(<supplement>Suppl. 1</supplement>): <fpage>S287</fpage>–<lpage>S296</lpage>.</citation>
</ref>
<ref id="bibr153-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zangaglia</surname><given-names>R.</given-names></name>
<name><surname>Pacchetti</surname><given-names>C.</given-names></name>
<name><surname>Pasotti</surname><given-names>C.</given-names></name>
<name><surname>Mancini</surname><given-names>F.</given-names></name>
<name><surname>Servello</surname><given-names>D.</given-names></name>
<name><surname>Sinforiani</surname><given-names>E.</given-names></name>
<etal/>
</person-group> (<year>2009</year>) <article-title>Deep brain stimulation and cognitive functions in Parkinson’s disease: a three-year controlled study</article-title>. <source>Mov Disord</source> <volume>24</volume>: <fpage>1621</fpage>–<lpage>1628</lpage>.</citation>
</ref>
<ref id="bibr154-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zgaljardic</surname><given-names>D.J.</given-names></name>
<name><surname>Borod</surname><given-names>J.C.</given-names></name>
<name><surname>Foldi</surname><given-names>N.S.</given-names></name>
<name><surname>Mattis</surname><given-names>P.</given-names></name>
</person-group> (<year>2003</year>) <article-title>A review of the cognitive and behavioral sequelae of Parkinson’s disease: relationship to frontostriatal circuitry</article-title>. <source>Cogn Behav Neurol</source> <volume>16</volume>: <fpage>193</fpage>–<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr155-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zibetti</surname><given-names>M.</given-names></name>
<name><surname>Torre</surname><given-names>E.</given-names></name>
<name><surname>Cinquepalmi</surname><given-names>A.</given-names></name>
<name><surname>Rosso</surname><given-names>M.</given-names></name>
<name><surname>Ducati</surname><given-names>A.</given-names></name>
<name><surname>Bergamasco</surname><given-names>B.</given-names></name>
<etal/>
</person-group> (<year>2007</year>) <article-title>Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus</article-title>. <source>Eur Neurol</source> <volume>58</volume>: <fpage>218</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr156-1756285611423412">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ziemssen</surname><given-names>T.</given-names></name>
<name><surname>Reichmann</surname><given-names>H.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Non-motor dysfunction in Parkinson’s disease</article-title>. <source>Parkinsonism Relat Disord</source> <volume>13</volume>: <fpage>323</fpage>–<lpage>332</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>